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ORAL DRUG DELIVERY SYSTEMS 
            Oral drug delivery is the most widely used route of administration among all the 
routes that have been developed for systemic delivery of drugs. Despite tremendous 
advancement in drug delivery, oral route is considered most convenient , uncomplicated, 
and safe due to its ease of administration, patient acceptance and cost effective 
manufacturing process. Most of the pharmaceutical products designed for oral delivery 
are immediate release types which are designed for rapid absorption of drug.
1
 
CAPSULES
2 
Capsules are solid dosage forms in which the medication is contained within 
gelatin shells. The medication may be a powder, a liquid or a semisolid mass. 
Advantages 
 Neat and elegant in appearance. 
 Enclosing the medication within capsule shells provides atasteless, 
odourless means of administering medication. 
 The ready solubility of gelatin at gastric pH provides rapidrelease of 
medication in the stomach. 
Types of capsules 
 Hard gelatin capsules 
 It consists of two pieces in the formof cylinders: the shorter piece “cap” 
andthe longer piece “body”. 
 The shells consist largely of gelatin,sugar and water. 
 Size of capsules: 
 
Size 000 00 0 1 2 3 4 5 
Volume 1.37 0.95 0.68 0.50 0.37 0.30 0.21 0.13 
Table 1: Size of capsule shells 
 Soft gelatin capsules 
 It consist of a continuous gelatin shell surrounding aliquid core. 
 It is formed, filled, and sealed in one operation. 
 It is oblong, spherical, elliptical in shape. 
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 The capsule shell consists of gelatin, water andplasticizer. 
 Plasticizer makes the shell elastic.e.g. glycerol, sorbitol and propylene 
glycol. 
 
CONTROLLED RELEASE DRUG DELIVERY SYSTEMS (CDDS)
3
 
                                Controlled release drug delivery system was designed to deliver for a 
prolongedperiod. Safe and effective blood levels are maintained for longer period as the 
system continues to deliver the drug. CDDS usually results in constant blood levels of the 
drug as compared to the uncontrolled fluctuations observed when multiple doses of quick 
releasing conventional dosage forms are administered to a patient. 
                                The driving force behind the development of sustained release 
formulations is the wish to extend the effective half-life of the drug and hence reduce dosing 
frequency or to minimize the differences between peak and trough plasma levels. 
Advantages 
Controlled release products offer many potential benefits over conventional 
dosage formulations , they are 
 Avoid patient  compliance 
 Less total drug is used 
 Minimize local side effects and systemic side effects 
 Obtain less reduction in drug activity in chronic use  
 Minimize the drug accumulation with chronic dosing 
 Improve efficiency in treatment and cures the condition more promptly 
 Bioavailability of some drugs is improved 
 Make use of special effects, e.g., sustained release of aspirin for morning relief of 
arthritis by dosing before bed. 
Disadvantages 
 Decreased systemic availability in comparison to immediate release formulation 
or conventional dosage forms, which may be due to incomplete release, increased 
first-pass metabolism, increased instability, insufficient residence time for 
complete release, site specific absorption on, pH dependent stability,etc. 
 Retrieval of drug is difficult in case of  toxicity, poisoning or hypersensitivity 
reactions. 
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 Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths. 
 Stability problems. 
GASTRORETENTIVE DRUG DELIVERY SYSTEMS
1,4
 
                            Dosage form with a prolonged gastric residence and controlled drug 
delivery are called as GRDDS. Oral controlled release dosage forms are developed due to 
their therapeutic advantages such as patient compliance, ease of administration and flexibility 
in formulation. However this approach has several physiological difficulties such as inability 
to locate the dosage form at the desired region of the gastrointestinal tract (GIT) due to 
variable gastric emptying time. The gastric emptying time in human normally ranges from 2-
3 hours through which the major absorption zone (stomach and upper part of intestine) passes 
through that so the dosage form can result in incomplete drug absorption from the delivery 
system and leading to reduced efficacy of the administered dose. Therefore, the control of 
placement of a drug delivery system in a specific region of the GIT offers greater advantage. 
The drugs characterized by a narrow absorption window in the GIT or drugs with a stability 
problem in the intestine can be benefitted by this approach. These have led to the 
development of a unique oral controlled release dosage form with gastro retentive properties. 
After oral administration, such a dosage form would be retained in the stomach and release 
the drug there in a controlled and prolonged manner, so that the drug could be supplied 
continuously to its absorption sites in the upper GIT. 
 
ANATOMICAL AND PHYSIOLOGICAL ASPECTS OF THE STOMACH
4,5
 
                A basic understanding of the anatomical and physiological aspects of 
the stomach isneeded for a pharmaceutical formulator to develop successful gastro 
retentive formulation. The main function of the stomach is to process and transport food. 
It serves as a short‐term storage reservoir, allowing a rather large meal to be consumed 
quickly.Anatomically the stomach is divided into 3 regions: fundus, body, and antrum 
(pylorus). The proximal part made of fundus and body acts as a reservoir for undigested 
material, whereas the antrum is the main site for mixing motions and act as a pump for 
gastric emptying by propelling actions. 
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Fig. 1: Anatomical representation of the stomach 
 
Stomach Physiology
5,6
 
                    The stomach is an expanded section of the digestive tube between the 
oesophagus and small intestine. The wall of the stomach is structurally similar to the 
other parts of the digestive tube, with the exception that stomach has an extra, oblique 
layer of smooth muscle inside the circular layer, which aids in the performance of 
complex grinding motions. In the empty state, the stomach is contracted and its mucosa 
and sub mucosa are thrown up into distinct folds called rugae. 
The four major types of secretary epithelial cells that cover the surface of the stomach 
and extend down into gastric pits and glands. They are  
 Mucous cells secrete alkaline mucus that protects the epithelium against shear 
stress and acid.  
 Parietal cells secrete hydrochloric acid.  
 Chief cells secrete pepsin, a proteolytic enzyme.  
 G cells secrete the hormone gastrin. The contraction of gastric smooth muscle 
serves two basic functions:  
• Ingested food is crushed, ground, mixed and liquefying to form Chyme.  
• Chyme is forced through the pyloric canal into the small intestine, a  
process called gastric emptying. 
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Gastric emptying
5,6
 
                   Gastric emptying occurs during fasting as well as fed states. 
Thepattern of motility is however distinct in the 2 states.During the fasting state, an 
interdigestive series of electrical events take place,which cycle both through stomach and 
intestine every 2 to 3 hours. This is called the interdigestive myloelectric cycle or 
migrating myloelectric cycle (MMC), which is further divided into following 4phases 
1. Phase I (Basal phase) lasts from 30 to 60 minutes with rarecontractions. 
2. Phase II (Preburst phase) lasts for 20 to 40 minutes withintermittent action potential 
and contractions. As the phaseprogresses the intensity and frequency also increases 
gradually. 
3. Phase III (burst phase) lasts for 10 to 20 minutes. It includesintense and regular 
contractions for short period. It is due tothis wave that all the undigested material is swept 
out of thestomach down to the small intestine. It is also known as thehousekeeper wave. 
4. Phase IV lasts for 0 to 5 minutes and occurs between phases IIIand I of 2 consecutive  
Cycles. 
 
 
Fig.2: Motility pattern in GIT 
 
FACTORS AFFECTING GASTRIC RESIDENCE TIME OF FDDS
4,7,8
 
                  The stomach anatomy and physiology contain parameters to be 
considered in the development ofgastroretentive dosage forms. To pass through the 
pyloric valve in to the small intestine the particle size should be in the range of 1 to 2 
mm. The most important parameters controlling the gastric retention time (GRT) of oral 
dosage forms include: 
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical College. Page 6 
 
1. Density of dosage forms 
           Density of the dosage form should be less than the gastric 
contents(1.004gm/ml). 
2. Shape and size of the dosage forms 
                       Dosage form unit with a diameter of more than 7.5 mm are reported to 
have an increased GRT competed to with those with a diameter of 9.9 mm. The dosage 
form with a shape tetrahedron and ring shapedevices with a flexural modulus of 48 and 
22.5 kiloponds per Square inch (KSI) is reported to have better GITretention 90 to 100 % 
retention at 24 hours compared with other shapes. 
3. Viscosity grade of polymer 
                       Drug release and floating properties of FDDS are greatly affected 
byviscosity of polymers and their interaction. Low viscosity polymers(e.g., HPMC K100 
LV) were found to be more beneficial than highviscosity polymers (e.g., HPMC K4M) in 
improving floatingproperties. In addition, a decrease in the release rate was observedwith 
an increase in polymer viscosity. 
3. Food intake and its nature 
                        Food intake, viscosity and volume of food, caloric value and frequency of 
feeding have a profound effect on the gastric retention of dosage forms. The presence or 
absence of food in the gastrointestinal tract (GIT) influences the gastric retention time 
(GRT) of the dosage form. Usually the presence of food in the gastrointestinal tract (GIT) 
improves the gastric retention time (GRT) of the dosage form and thus, the 
drugsabsorption increases by allowing its stay at the absorption site for a longer period. 
Again, increase in acidity and caloric value shows down gastric emptying time (GET), 
which can improve the gastric retention of dosage forms.  
4. Concomitant intake of drugs 
              Drugs such as prokinetic agents (e.g., metoclopramide and cisapride), 
anti Cholinergics (e.g., atropine or propantheline),opiates (e.g., codeine) may affect the 
performance of FDDS. The coadministration of GI‐motility decreasing drugs can 
increase gastric emptying time. 
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4. Effect of gender, posture and age 
Gender 
 Women have slower gastric emptying time than do men. Mean ambulatory GRT 
in meals  (3.4±0.4 hours) is less compared with their age and race‐matched female 
counterparts (4.6±1.2 hours), regardless of the weight, height and body surface. 
Age 
Low gastric emptying time is observed in elderly than do in younger subjects. 
Intrasubject and intersubject variations also are observed in gastric and intestinal transit 
time. Elderly people, especially those over 70 years have a significantly longer GRT. 
Posture 
i) Upright position 
An upright position protects floating forms against postprandial emptying because 
the floating form remains above the gastric contents irrespective of its size. Floating 
dosage forms show prolonged and more reproducible GRTs while the conventional 
dosage form sink to the lower part of the distal stomach from where they are expelled 
through the pylorus byantral peristaltic movements. 
ii) Supine position 
This position offers no reliable protection against early and erratic emptying. In 
supine subjects large dosage forms (both conventional and floating) experience prolonged 
retention. The gastric retention of floating forms appear to remain buoyant anywhere 
between the lesser and greater curvature of the stomach. On moving distally, these units 
may be swept away by the peristaltic movements that propel the gastric contents towards 
the pylorus, leading to significant reduction in GRT compared with upright subjects. 
 
SUITABLE DRUG CANDIDATES FOR GASTRORETENTION
6
 
In general, appropriate candidates for CRGRDF are molecules that have poor 
colonic absorption but arecharacterized by better absorption properties at the upper parts 
of the GIT: 
• Narrow absorption window in GI tract, e.g., Riboflavin and Levodopa 
• Primarily absorbed from stomach and upper part of GI tract, e.g., Calcium supplements, 
Chlordiazepoxide and Cinnarazine 
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• Drugs that act locally in the stomach, e.g., Antacids and Misoprostol 
• Drugs that degrade in the colon, e.g., Ranitidine HCl and Metronidazole 
• Drugs that disturb normal colonic bacteria e.g., Amoxicillin trihydrate 
 
APPROACHES TO GASTRORETENTION
9,10
 
Several techniques are reported in the literature to increase thegastric retention of drugs. 
1) Highdensitysystems 
These systems, which have a density of ~3g/cm3, are retained in the rugae of 
stomach and capable of withstanding its peristalticmovements.The only major drawback 
with these systems is that it is technicallydifficult to manufacture them with a large 
amount of drug (>50%)and achieve required density of 2.4‐2.8g/cm3. Diluents such as 
barium sulphate (density= 4.9), zinc oxide, titanium oxide, and ironpowder must be used 
to manufacture such high‐density formulation. 
 
 
Fig.3:High density systems 
 
2) Swelling and expanding systems 
These systems are also called as “Plug type system”, since theyexhibit tendency 
to remain logged in the pyloric sphincters. These polymeric matrices remain in the gastric 
cavity for several hourseven in fed state. 
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.  
Fig.4: Swellable tablet in stomach 
By the selection of polymer with  proper molecular weight andswelling properties 
controlled and sustained drug release can beachieved. Upon coming in contact with 
gastric fluid, the polymerimbibes water and swells. The extensive swelling of these 
polymersis a result of the presence of physical‐chemical cross links in thehydrophilic 
polymer network. These cross link prevents thedissolution of polymer and thus maintain 
the physical integrity ofthe dosage form. A high degree of cross linking retards the 
swellingability of the system and maintains its physical integrity forprolonged period. On 
the other hand, a low degree of cross linkingresults in extensive swelling followed by the 
rapid dissolution ofpolymer. 
 
 
Fig.5: Different geometric forms of unfoldable systems 
3) Incorporating delaying excipients: 
Another delayed gastric emptying approach of interest include feeding of 
digestible polymers or fatty acid salts that charges themotility pattern, of the stomach to a 
fed stage thereby decreasing thegastric emptying rate and permitting considerable 
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prolongation ofthe drug release. Prolongation of GRT of drug delivery systemconsists of 
incorporating delaying excipients like trietanolamine myristate in a delivery system. 
4) Modified systems: 
Systems with non disintegrating geometric shape molded from silastic elastomers 
or extruded from polyethylene blends, whichextend the GRT depending on size, shape 
and flexural modules ofdrug delivery device. 
5) Mucoadhesive & Bioadhesive systems 
Bioadhesive drug delivery systems are used to localize a deliverydevice within 
the lumen to enhance the drug absorption in a site specific manner. This approach 
involves the use of bioadhesive polymers, which can adhere to the epithelial surface in 
the stomach.Some of the most promising excipients that have been usedcommonly in 
these systems include polycarbophil, carbopol, lectins,chitosan, CMC and gliadin, etc. 
6) Floating systems 
Floating drug delivery systems (FDDS) have a bulk density less thangastric fluids 
and so remain buoyant in the stomach withoutaffecting the gastric emptying rate for a 
prolonged period of time.While the system is floating on the gastric contents, the drug 
isreleased slowly at the desired rate from the system. After release ofdrug, the residual 
system is emptied from the stomach. Floatationof a drug delivery system in the stomach 
can be achieved byincorporating floating chamber filled with vacuum, air, or inert gas. 
 
MECHANISM OF FLOATING SYSTEMS
11
 
Floating drug delivery systems (FDDS) have bulk density lesser than gastric fluid, 
sothey remain buoyant in the stomach without affecting the gastric emptying rate for 
aprolonged period of time, while the system is floating on the gastric contents the 
drugreleased slowly at the desired rate from the system. However, besides aminimal 
gastric content needed to allow the proper achievement of the buoyancy 
retentionprinciple, a minimal level of floating force (F) is also required to keep the 
dosage formreliably buoyant on the surface of the meal. To measure the floating force 
kinetics, a novelapparatus for determination of resultant weight has been reported. The 
apparatus operates bymeasuring continuously the force equivalent to F (as function of 
time) that is required tomaintain the submerged object. The object floats better if F is on 
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the higher positive side. This apparatus helps in optimizing FDDS with respect to 
stability and durability of floating force proceed in order to prevent the drawbacks of 
unforeseeable intragastric buoyancy capability variations. 
F =F Buoyancy-F Gravity=(Df-Ds) gv 
                               Where, 
F = total vertical force; 
Df = fluid density; 
Ds =object density 
V = volume 
g =acceleration due to gravity 
 
Fig.6: Mechanism of floating systems 
 
ADVANTAGES OF FLOATING DOSAGE FORM
9
 
(1) These systems are particularly advantageous for drugs that arespecifically absorbed 
from stomach or the proximal part of the smallintestine, e.g., riboflavin and furosemide. 
(2) The fluctuations in plasma drug concentration are minimized, and 
concentration‐dependent adverse effects that are associatedwith peak concentrations can 
be prevented. This feature is of specialimportance for drugs with a narrow therapeutic 
index. 
(3) The efficacy of the medicaments administered utilizing thesustained release principle 
of floating formulation has been found tobe independent of the site of particular 
medicaments. 
(4) Complete absorption of the drug from the floating dosage form isexpected even at the 
alkaline pH of the intestine. The dissolution ofthe drug in gastric fluid occurs and then the 
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dissolved drug isavailable for absorption in the small intestine after emptying of 
thestomach contents. 
(5) Poor absorption is expected when there is vigorous intestinalmovement and a shorted 
transit time as might occur in certain typeof diarrhea. Under such circumstances it may be 
advantageous tokeep the drug in floating condition in stomach to get a relatively 
better response. 
(6) Drugs that have poor bioavailability because of site‐specificabsorption from the upper 
part of the gastrointestinal tract arepotential candidates to be formulated as floating drug 
deliverysystems, thereby maximizing their absorption. A significantincrease in the 
bioavailability of floating dosage forms (42.9%)could be achieved as compared with 
commercially available 
LASIX tablets (33.4%) and enteric‐coated LASIX‐long product(29.5%). 
 
LIMITATIONS OF FLOATING DRUG DELIVERY SYSTEMS
9
 
(1) A high level of fluid in the stomach is required for drug deliveryto float and work 
efficiently. 
(2) Drugs which have stability and solubility problems in GIT arenot suitable candidates 
for these types of systems. 
(3) Drugs such as Nifedipine, which under goes first passmetabolism may not be 
desirable for the preparation of these types of systems. 
(4) Drugs which are irritant to gastric mucosa are also notdesirable. 
(5) The drug substances that are unstable in the acidicenvironment of the stomach are not 
suitable candidates to be incorporated in the systems incorporated in the systems. 
 
CLASSIFICATION OF FDDS BASED ON MECHANISM OFBUOYANCY
9
 
A) Single unit 
Single unit dosage forms are easiest to develop but suffers from therisk of losing 
their effects too early due to their all‐or‐none emptyingfrom the stomach and, thus they 
may cause high variability inbioavailability and local irritation due to large amount of 
drugdelivered at a particular site of the gastro intestinal tract. 
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Non-effervescentsystems 
One or more gel forming, highly swellable, cellulosic hydrocolloids(e.g. hydroxyl 
ethyl cellulose, hydroxyl propyl cellulose,hydroxyl propyl methyl cellulose [HPMC] and 
sodium carboxy methylcellulose), polysaccharides, or matrix forming 
polymers(e.g.,polycarbophil, polyacrylates, and polystyrene) are incorporated inhigh 
level (20‐75% w/w) to tablets or capsules.For the preparation of these types of systems, 
the drug and the gelforminghydrocolloid are mixed thoroughly. After oraladministration 
this dosage form swells in contact with gastric fluidsand attains a bulk density of < 1. The 
air entrapped within theswollen matrix imparts buoyancy to the dosage form. The so 
formedswollen gel‐like structure acts as a reservoir and allows sustainedrelease of drug 
through the gelatinous mass. 
Effervescent systems or gas generating systems 
These are matrix types of systems prepared with the help of swellable polymers 
such as methylcellulose and chitosan andvarious effervescent compounds, e.g. sodium 
bicarbonate, tartaricacid, and citric acid. They are formulated in such a way that when 
incontact with the acidic gastric contents, CO2 is liberated and getsentrapped in swollen 
hydrocolloids, which provides buoyancy to thedosage forms. The optimal stoichiometric 
ratio of citric acid andsodium bicarbonate for gas generation is reported to be 0.76:1. 
B) Raft Forming systems 
Raft Forming systems have received much attention for the delivery of antacids 
and drug delivery for gastrointestinal infections and other disorders. The mechanism 
involved in the raft formation includes the formation of a viscous cohesive gel in contact 
with gastric fluids, wherein each portion of the liquid swells forming a continuous layer 
called a raft. The raft swells in the gastric fluid because of the low bulk density created by 
the formation of CO2. Usually, the system contains a gel forming agent and alkaline 
bicarbonates or carbonates responsible for the formation of CO2to make the system less 
dense and able to float on the gastric fluids. It is used for the treatment of Helicobacter 
pylori infections in the GIT. 
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Fig.7: Raft forming system 
 
C) Multiple unit 
Single unit formulations are associated with problems such assticking together or 
being obstructed in gastrointestinal tract, whichmay have a potential danger of producing 
irritation. Multiple unitsystems avoid the ‘all‐or‐none’ gastric emptying nature of 
singleunitsystems. It reduces the intersubject variability in absorption and the probability 
for dose dumping is lower. 
Effervescent systems 
A multiple unit system comprises of calcium alginate core and calcium 
alginate/PVA membrane, both separated by an air compartment was prepared. In 
presence of water, the PVA leachesout and increases the membrane permeability, 
maintaining the integrity of the air compartment.  Increase in molecular weight and 
concentration of PVA, resulted in enhancement of the floatingproperties of the system. 
Freeze‐drying technique is also reported for the preparation of floating calcium alginate 
beads. Sodium alginate solution is added drop wise into the aqueous solution of calcium 
chloride, causing the instant gelation of the droplet surface, due to the formation of 
calcium alginate. The obtained beads are freeze-dried resulting in a porous structure, 
which aid in floating.  
Non-effervescent systems
11
 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescentFDDS are gel forming or highly swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymers such as 
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Chitosan and Carbopol. 
The various types of this system are as: 
1. Colloidal Gel Barrier Systems 
Hydro-dynamically balanced system (HBS) of this type contains drug with gel 
forming or swellable cellulose type hydrocolloids, polysaccharides and matrix forming 
polymers. They help in prolonging the GI residence time and maximize drug reaching its 
absorption site in the solution form ready for absorption. These systems incorporate high 
levels (20 to 75 % w/w) of one or more gel forming highly swellable cellulose type 
hydrocolloids e.g. Hydroxy ethyl cellulose, Hydroxy propyl cellulose, Hydroxy propyl 
methyl cellulose, Sodium carboxy methyl cellulose incorporated either in tablets or  
capsules. 
2. Micro porous compartment system 
This technology is comprised of encapsulation of a drug reservoir inside a micro 
porous compartment with pores along its top and bottom surfaces. The peripheral walls of 
thedrug reservoir compartment are completely sealed to prevent any direct contact of 
gastricmucosal surface with undissolved drug. In stomach, the floatation chamber 
containingentrapped air causes the delivery system to float over the gastric contents. 
Gastric fluid entersthrough the pores, dissolves the drug and carries the dissolved drug for 
continuous transportacross the Intestine for absorption. 
 
 
Fig.8: Micro porous intra-gastric floating drug delivery device 
3. Hollow Microspheres 
Hollow microspheres (Microballoons), loaded with drug in their outer polymer 
shellsare prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethanesolution of the drug and an enteric acrylic polymer is poured into an 
agitated aqueoussolution of PVA that is thermally controlled at 40 °C. The gas phase 
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generated in dispersedpolymer droplet by evaporation of dichloromethane forms an 
internal cavity in microsphereof polymer with drug. The Microballoons float 
continuously over the surface of acidicdissolution media containing surfactant for more 
than 12 hours. 
Fig.9: Mechanism of micro balloon formation by emulsion-solvent diffusion 
Method 
4. Alginate Beads 
Multi-unit floating dosage forms were developed from freeze dried calcium 
alginate.Spherical beads of approximately 2.5 mm diameter can be prepared by dropping 
sodiumalginate solution into aqueous solution of calcium chloride, causing precipitation 
of calciumalginate leading to formation of porous system, which can maintain a floating 
force for over12 hours. When compared with solid beads, which gave a short residence 
time of 1 hour, these floating beads gave a prolonged residence time of more than 5.5 
hours. 
 
Fig.10:Alginate beads 
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METHOD OF PREPARATION: 
Alginate beads can be prepared by two methods. They are 
o Ionotropic gelation method 
o Emulsion gelation method 
 
Ionotropic gelation method
12
 
Alginate beads can also be prepared by Ionotropic gelation method. IGM  is based 
on the ability of polyelectrolytes to cross link in the presence of counter ions to form 
hydrogel beads also called as gelispheres. Gelispheres are spherical crosslinked 
hydrophilic polymeric entity capable of extensive gelation and swelling in simulated 
biological fluids and the release of drug through it controlled by polymer relaxation. The 
hydrogel beads are produced by dropping a drug-loaded polymeric solution into the 
aqueous solution of polyvalent cations. The cations diffuses into the drug-loaded 
polymeric drops, forming a three dimensional lattice of ionically crosslinked moiety. 
Biomolecules can also be loaded into these gelispheres under mild conditions to retain 
their three dimensional structure 
     Polyelectrolyte solution 
[Sodium Alginate (-)/Gellan gum (-)/CMC (-)/Pectin (-)/ Chitosan (+) + Drug] 
           ↓ 
Added drop wise under magnetic stirring by needle 
↓ 
Counter ion solution 
[Calcium chloride solution (+)/Sodium tripolyphosphate (-)] 
↓ 
Gelispheres 
Emulsion gelation method: 
Oil entrapped Floating Alginate beads is prepared by Emulsion Gelation method. 
In this method, Sodium alginate solution is prepared by dissolving sodium alginate  
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indistilled demineralized water with agitation. Oil phase in the concentration from 10% to 
30% v/v  is added with high shear mixing. The dug to be formulated is then dispersed in 
the formed emulsion. This mixture was extruded, using syringe of required needle gauge 
size into calcium chloride solution(1-5%w/v). The gel beads were allowed to stand in 
solution for some time with mild stirring (curing time) before being separated and dried.   
EMULSION GELATION METHOD 
Sodium Alginate + Distilled water 
↓(Dissolve) 
                                               Add Oil phase 
              ↓(High shear mixing) 
Formation of O/W Emulsion 
                                                         ↓ 
          Drug is Dispersed 
                                                         ↓ 
                                         Extruded into Calcium chloride solution 
                ↓ 
Gel beads allowed to stand in solution(curing time) 
         ↓ 
                                   Collected, Washed and Dried   
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Fig.11: Experimental setup of Preparation of Alginate beads 
FUTURE SCOPE OF FLOATING MULTIPLE UNIT DRUG DELIVERY SYSTEM
13
 
Floating multiparticles can greatly improve the pharmacotherapy of the stomach 
through local drug release, used to eradicate Helicobacter pylori from the sub-mucosal 
tissue of the stomach most effectively and making it possible to treat stomach and 
duodenal ulcers, gastritis and oesophagitis. This system allows administration of non- 
systemic, controlled release antacid formulation containing calcium carbonate and also 
locally acting anti-ulcer drug (such as Lansoprazole) in stomach. Byoyant micro particles 
are considered as a beneficial strategy for the treatment of gastric and duodenal cancers. 
Floating multiparticles of NSAID’s are very effective for reducing their major 
side effect, gastric irritation as well as for controlled release.They may be used as a 
carrier for the drugs having narrow absorption windows, for example antiviral, antifungal 
and antibiotics.In addition, by continually supplying the drug to its most efficient site of 
absorption n, the dosage form may allow for  more effective oral use of peptide and 
protein drugs such as calcitonin, erythropitin, vasopressin low molecular weight heparin. 
 
 
 
 
SYRINGE CONTAINING SODIUM  
ALGINATE EMULSION 
CALCIUM CHLORIDE 
SOLUTION 
MAGNETIC STIRRER 
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Table2:List of Floating multiparticulate Marketed prepatrations 
 
S.No. 
 
BRAND 
NAME 
 
DRUG(DOSE) 
 
 
COMPANY 
 
DOSAGE 
FORM 
 
1. 
 
Conviron 
 
Ferrous sulfate 
 
Ranbaxy,India 
 
Colloidal gel 
forming 
FDDS 
 
 
2. 
 
Cytotec 
 
Misopristol 
(100/200mcg) 
 
Pharmacia 
 
Bilayer 
floating 
capsule 
 
 
3. 
 
Topalkan 
 
Al-Mg Antacid 
 
Pierre Fabre 
Drug, France 
 
Floating 
liquid 
alginate 
preparation 
 
 
4. 
 
MODAPAR 
 
Levodopa(100mcg) 
Benserzide(25mcg) 
 
Roche 
products, USA 
 
Floating CR 
capsules 
 
 
5. 
 
Liquid 
Gavison 
 
AluminiumHydroxide 
(95 mg) 
Magnesium 
carbonate(358mg) 
 
GSK, India 
 
Effervescent 
floating 
liquid 
alginate 
preparation 
 
 
6. 
 
Valrelease 
 
Diazepam(15mg) 
 
Hoffmann-
LaRoche, USA 
 
Floating 
capsules 
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1. JadupatiMalakaret al.14 formulated and evaluated (in-vitro and in-vivo) floating 
capsules containing Alginate based beads of Salbutamol sulfate. Salbutamol 
sulfate-loaded oil-entrapped beads were prepared and capsulated within hard 
gelatin capsules (size 1). The effects of HPMCK4M and potato starch weight 
masses on drug encapsulation efficiency (DEE) of beads and cumulative drug 
release at 10 h (R10 h) from capsules was analyzed by 32factorial design. The 
optimization results indicate increasing of DEE in the oil-entrapped beads and 
decreasing R10 h from capsules with increment of HPMC K4M and potato starch 
weight masses. These capsules showed floatation over 6 h and sustained drug 
release over10 h in gastric pH (1.2). In vivo X-ray imaging study of optimized 
floating capsules in rabbits showed stomach-specific gastro retention over a 
prolonged period. 
 
2. Durgajaiswalet al.15formulated and evaluated oil entrapped floating alginate 
beads of ranitidine hydrochloride.The objective of this investigation was to 
develop a multi-unit gastroretentive sustained release dosage form of a water 
soluble drug, Ranitidine hydrochloride. A new emulsion gelation technique was 
used to prepare emulsion gel beads using sodium alginate and pectin as polymers 
and their sustaining abilities were studied. The effects of factors like 
concentration of oil, curing time, drug: polymer ratio, alginate: pectin ratio and 
curing agent on drug entrapment efficiency, floating lag time, morphology and 
drug release were studied.The results show that these beads can entrap even a 
water soluble drug as Ranitidine hydrochloride in sufficient amount and also can 
successfully deliver the drug in stomach for a prolong duration of time without 
using any organic solvent and any time consuming step in the preparation. 
 
3. Mowafaq M et al.16formulated and evaluated Trimetazidinedihydrochloride 
Floating beads. The study’s objective was to develop gastro-retentivefloating  
beads that control the drug release  which is freely soluble in water and suffers 
from rapid absorption and relatively short plasma half- life (6.0±1.4). By 
emulsion gelation method, trimetazidine floating beads were prepared using 
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sodium alginate,HPMC and peppermint oil. The effect of sodium alginate 
concentrations (2,3 and 4%w/v), peppermint oil percentage (15,20 and 25%v/v) 
and HPMC type on floating properties besides in-vitro drug release from the 
beads were studied. According to similarity factor, formulas which contain 
2%w/v sodium alginate, 20%v/v oil and HPMC (15 000 centipoises) were the 
best formulas that showed higher similarity factor in drug release in comparison 
the reference product, with good floating ability. 
 
 
4. SwarnkarKedar Prasadet al.17 reported on the Preparation and Optimization of 
oral floating alginate gel beads of famotidine. The objective was to prepare and 
optimize an oral floating alginate gel beads of famotidine using gas generating 
agent like sodium bicarbonate and Corn oil. The effect of different concentrations 
of sodium alginate, calcium chloride and famotidine were used and their  
Morphological analysis, Buoyancy, Encapsulation efficiency and in-vitro drug 
release behavior in simulated gastric fluid were carried out. Size of all the beads 
was found spherical and uniform and Buoyancy study showed that only F-3 to F-
13 was floating. It was clearly seen that famotidine release from uncoated beads 
in a considerable “burst” during the first 30 min, due to rapid water ingress and 
creation of aqueous channels. 
 
5. Mohd Abdul Hadiet al.18developed Floating multiple unit controlled-release 
beads of Zidovudine for the treatment of AIDS. The controlled release beads was 
prepared by Ionotropic gelation method using sodium alginate containing KHCO3 
as the gas-forming agent. The beads were subjected to in-vitro drug release, 
kinetic studies and stability studies. FTIR and DSC showed there was no 
interaction between drug and polymers.The percentage drug content in the beads 
ranged from 93.76±0.44 to 98.14±1.10 and the in-vitro percentage release from 
the beads at the end of 12 hours ranged from 86.10 to 96.83. The kinetics study 
revealed that the drug was released by zero-order kinetics. The stability studies 
REVIEW OF LITERATURE 
 
Department of Pharmaceutics, Madras Medical College. Page 23 
 
showed that there were no significant changes in drug content, physiochemical 
parameters and release pattern. 
 
6. Azhar Danish khan et al.19 formulated and evaluated Floating beads of 
verapamil hydrochloride. Emulsion gelation technique was used to prepare 
emulsion gelation beads using sodium alginate as the polymer. The effects of 
factors like concentration of oil, drug:poymer ratio and alginate:pectin ratio on 
entrapment efficiency , floating lag time, morphology and drug release were 
studied. The gel beads prepared with combination of alginate and pectin showed 
greater sustainability compared to alginate in terms of drug release. The results 
show that these beads can entrap even a water soluble drug as Verapamil 
hydrochloride in sufficient amount and also can successfully deliver the drug in 
stomach for a prolong duration of time without using any organic solvent and any 
time consuming step in the preparation. 
 
7. SundharamoorthyRevathiet al.20formulated and evaluated Stavudine loaded 
Sodium alginate beads by Ionotropic gelation method. The objective of the 
present study was to develop hydrophilic and hydrophobic polymer based novel 
control release Stavudine beads for achieving the action upto 12 hours and to 
characterize the efficacy and to 
analyze
 the effect of various polymers like sodium 
alginate, HPMC and ethyl cellulose. From the results, it was stated that the 
formulation F-4 appears to be promising system for the sustained release for 
antiretroviral therapy based on actual drug content, % encapsulation efficiency 
and in-vitro drug release data. 
 
8. Elmeshad AN et al.21reported on the Floating Furosemide gel beads: in-vitro and 
in-vivo evaluation. Buoyant beads enclosing furosemide were prepared by cross-
linking chitosan with dioctyl sodium sulphosuccinate (DOSS) and characterized 
according to: entrapment efficiency, in vitro release, in vitro and in vivo 
buoyancy. The effect of various factors (DOSS and chitosan concentrations, drug: 
polymer ratio and loading technique) on bead properties were assessed. 
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Interaction between chitosan and DOSS was evaluated by DSC and FTIR. SEM 
demonstrated that the dried beads were spherical in shape with an inward cavity 
enclosing furosemide in the range of 1.8-62.25 %. Most beads floated over SGF 
for 12 h. Beads retarded the release of furosemide compared to pure drug powder 
and Lasix tablets. The t50 % ranged from 1.79-4.1 h and release followed zero or 
diffusion kinetics. Beads remained buoyant in the stomach of dogs for 6 h. 
Beadswere stable at 40°C and 75 % RH for 3 months. 
 
9. JharanaMallick et al.22developed Alginate beads of Ibuprofen for oral sustained 
drug delivery: An in-vitro evaluation.Alginate beads were formulated under 
different conditionsof polymer concentration at constant speed. The beads were 
evaluated according toparticle size, drug content, percentage yield, moisture 
content by Karl Fischer titration, bulkdensity, tapped density, Carr’s index. In 
vitro release of Ibuprofen from the beads wasstudied in simulated intestinal fluid 
(SIF, pH 7.4). The investigation revealedthat the beads produced with 2.5% 
(W/V) sodium alginate had the optimum prolongedrelease pattern. The beads 
produced using 2% (W/V) Sodium alginate had the highestdelayed release of the 
incorporated drug, whereas other ratios of drug polymer had the fastestrelease. 
The in-vitro dissolution studies appeared to have adequately described the 
releaseprocess as about 8 to 10 hours. The SEMstudy revealed thespherical shape 
and the presence of pores which is effective for loading of the dose. The X-
Raydiffraction study, DSC, TGA and FTIR spectroscopy  showed no drug 
polymer interaction.This impliesthat  formulations of Ibuprofen-sodium alginate 
microspheres are likely to offer a reliable meansof delivering Ibuprofen by the 
oral route. 
 
10. Murata Y et al.23 studied on the Use of floating alginate beads for stomach- 
specific drug delivery.Two types of alginate gel beads capable of floating in the 
gastric cavity were prepared. The first, alginate gel bead containing vegetable oil 
(ALGO), is a hydrogel bead and its buoyancy is attributable to vegetable oil held 
in the alginate gel matrix. The model drug, metronidazole (MZ), contained in 
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ALGO released gradually into artificial gastric juice, the release rate being 
inversely related to the percentage of oil. The second, alginate gel bead containing 
chitosan (ALCS), is a dried gel bead with dispersed chitosan in the matrix. The 
drug-release profile was not affected by the kind of chitosan contained in ALCS. 
When ALCS containing MZ was administered orally to guinea pigs, it floated on 
the gastric juice and released the drug into the stomach. Furthermore, the 
concentration of MZ at the gastric mucosa after administration of ALCS was 
higher than that in the solution, though the MZ serum concentration was the same 
regardless of which type of gel was administered. These release properties of 
alginate gels are applicable not only for sustained release of drugs but also for 
targeting the gastric mucosa. 
 
11. Thakur AtulkumarRanvirsingh et al.24formulated and evaluated Floating 
Alginate Beads of an Anti Ulcer Drug. The present research work was focused on 
the development of a multiple unit floating formulation using naturalpolymers 
(sodium alginate and Xanthan gum) and gas-forming agent( sodium bicarbonate) 
by employing ionotropic gelation method with Esomeprazole as a model drug. 
The formulated beads were characterized for particle size, percentage drug 
entrapment efficiency, in-vitro buoyancy and in-vitro drug release. Percentage 
drug entrapment was between 52.5% - 87.5 % and buoyancy was found to be 
between 84% - 98%. The in-vitro drugrelease results indicated that increasing the 
concentration of sodium alginate with respect to the drug resulted in further 
retardingthe drug release.  
 
12. Pranav Kumar Reddy M et al.25prepared and evaluated Atenolol floating 
alginate beads as a controlled drug delivery system. Atenolol floating 
microspheres were prepared by the ionotropic gelation technique using HPMCand 
sodium alginate as polymers at different ratios. The 30ml of sodium alginate and 
HPMC solution in 9:1 ratio was prepared using 1%, 2% and 3% concentrations of 
polymers. The prepared formulations were characterized for their particle size, 
entrapment efficiency, drug content, and in-vitro drug release using 0.1N Hcl of 
REVIEW OF LITERATURE 
 
Department of Pharmaceutics, Madras Medical College. Page 26 
 
pH 1.2. The microspheres were found to be regular in shape and highly porous. 
Amongst 3 formulations prepared (F1-F3), F3 showed prolonged drug release and 
remain buoyant for more than 8 hours and suggested that increased polymer 
concentration gives slower release of drug and more duration of drug release in 
the stomach. 
 
13. Tapan Kumar Giriet al.26 reported on the Crosslinked biodegradable alginate 
hydrogel floating beads for stomach site specific controlled delivery of 
Metronidazole. In the present work, gastro retentive floating beads of sodium 
alginate (SA) were prepared through Ionotropic gelation with divalent Ca++ ions 
and covalent cross-linking with glutaraldehyde (GA). Metronidazole (MZ) was 
successfully encapsulated into beads by varying the amount of SA, xanthan gum, 
magnesium stearate, and GA. Encapsulation of MZ was up to 79.17%. However, 
with an increasing amount of GA in the matrix, the encapsulation efficiency was 
found to decrease significantly. Beads prepared without GA released 50% of the 
drug in 2.76h. GA treatment suppressed the drug release significantly. 
Compatibility of the drug with the polymers was examined using FTIR 
spectroscopy. DSC and X–ray diffraction studies XRD were carried out to 
examine the crystalline nature of the encapsulated drug. The drug was relatively 
stable and amorphous in the beads. 
 
14. Amal El Sayeh F et al.27reported on  Ketorolac tromethamine floating beads for 
oral application: Characterization and in-vitro/in-vivo evaluation.In the present 
work, the KT floating beads were prepared by extrusion congealing method 
utilizing calcium carbonate as a gas forming agent. The physical characters of the 
produced beads were investigated such as KT yield, KT loading, and entrapment 
efficiency of the drug. In addition, floating behavior, swelling, particle size, 
morphology and KT stability were also evaluated. In-vitro drug release study was 
carried out, and the kinetics of the release was evaluated using the linear 
regression method. Furthermore, the in vivo analgesic effect of KT after oral  
administration of the selected formula of floating beads (F10) was carried out 
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using hot plate and tail flick methods. Oral commercial KT tablets and KT 
solution were used for the comparison. The prepared beads remained floated for 
more than 8 h. The optimized formulation (F10) exhibited prolonged drug release 
(more than 8 h) and the drug release follows the Higuchi kinetic model, with a 
Fickian diffusion mechanism according to Korsmeyer- Peppas (n= 0.466). 
Moreover, F10 showed a sustained analgesic effect as compared to the 
commercial tablet. 
 
15. RammohanBeraet al.28formulated and evaluated (in-vitro) of Sunflower Oil 
Entrapped within Buoyant Beads of Furosemide.Sunflower oilentrapped buoyant 
alginate beads of furosemide were prepared by theemulsion-gelation technique. 
During the preparation of various batches ofbeads, the ratio of sunflower oil to 
water (v/v), the ratio of drug to polymer (w/w),were kept as variables at two 
levels; either high or low. Smooth, sphericalbeads with nominal weight variation 
were obtained. All batches of beads floatedfor 24 hours with a lag time of 5–10 
min. The release of drug followed for5 hours. Higuchi and first order kinetic 
modeling indicated a diffusion-controlledrelease of drug from the beads. The 
study also demonstrated the influence ofsunflower oil on drug entrapment (81–
95%) and in-vitro release. A higher levelof oil increased drug entrapment 
efficiency but retarded drug release rate ascompared to a lower level of oil 
containing beads. 
 
16. Karunapriyachitraet al.29reported on A helping hand for prinzmetals- 
Nifedipine floating beads. The work was aimed at investigating the floating bead 
formulations prepared by ionotropic gelation technique. The formulations were 
optimized for different weight ratios of sodium alginate and gas forming 
agent(Calcium carbonate). FH1(HPMC1:1), FH2 (HPMC1:2), FP1(PVP1:1) , 
FP2(PVP1:2) were evaluated for percent drug loading, drug entrapment 
efficiency, surface topography, buoyancy, in vitro release and release kinetics. 
FT-IR results have shown that drug and excipients are compatible. FH2 shows 
better gastro retention (69.62%), buoyancy property throughout the study and 
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results drug entrapment efficiency (83.3%), percent drug loading (82.3%) and 
release patterns are better compared to other formulations. The beads containing 
higher amounts of calcium carbonate demonstrated instantaneous, complete and 
excellent floating ability over a period of 24 hrs. This above mentioned 
formulation (FH2) could be a suitable composition for Nifedipine as a floating 
gastro retentive dosage form. 
  
17. Yadav M et al.30formulated and evaluated sustain release floating beads of anti 
hypertensive drug Ramipril. Drug and polymer compatibility was studied by 
subjecting physical mixtures of drug and polymers to FTIR. The beads were 
prepared by Ionotropic gelation method utilizing calcium carbonate as a gas 
forming agent. As gas-forming agents increased, the size and floating properties 
increased. The different concentrations of sodium alginate were used and their 
Morphological analysis, Buoyancy, Encapsulation efficiency and in-vitro drug 
release behaviour in simulated gastric fluid were carried out. The enhanced 
buoyancy and sustained release properties of CaCO3-containing beads make them 
an excellent candidate for floating drug dosage systems. 
 
18. Lohithasu D et al.31reported on Formulation development and evaluation of 
glyburide beads for controlled release.Beads were successfully prepared by 
Ionotropic Gelation Method using Sodium alginate, HPMC K100M, Carbopol 
940 and Calcium Chloride(fused) .The prepared beads were evaluated for various 
parameters like encapsulation efficacy, swelling index, Mean particle size, flow 
properties and in vitro release. The yields were varies from 88-93.8% and 
encapsulation efficacy is up to 91.2% which encourage the investigation. The 
dissolution was performed for 12 hours and the drug release was found to be 
99.42%..The in-vitrorelease  kinetics showed that it follows zero order. Hence, 
controlled release. 
 
19. SmritiMalviyaet al.32formulated and evaluated floating microbeads of 
Ciprofloxacin HCl by Emulsion gelation methodusing sodium alginate as the 
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polymer. The effects of factors likeconcentration of oil, curing time, drug: 
polymer ratio, alginate: pectin ratio and curing agent on drug entrapment 
efficiency, floating lag time, morphology and drug release were studied. 
Minimizing the curing time of beads leaded to enhanced drug entrapment 
efficiency. The use of sodium alginate and combinations of sodium alginate and 
pectin are used to study the effect on the sustaining property of the formed beads. 
It was found that sodium alginate was not sufficient to sustain the drug release at 
gastric pH. Instead of it, appropriate combination of alginate and pectin could 
provide the sustain release of drug. The results show that these beads can entrap 
even a water soluble drug as Ciprofloxacin in sufficient amount and also can 
successfully deliver the drug in stomach for a prolong duration of time.  
 
20. PeeushSinghalet al.33reported on Evaluation of Acyclovir loaded oil entrapped 
calcium alginate beads prepared by Emulsion Gelation method by altering 
polymer: cross linking agent ratio (sodium alginate/ Calcium chloride), oil 
concentrations (10%, 20% and 30% w/w) and drug: polymer (D: P) ratios (1:1, 
2:1 and 3:1). The beads were evaluated for diameter, surface morphology, 
encapsulation efficiency, buoyancy and invitro release. The results indicated that 
the percentage of oil plays an important role in controlling the floating of oil-
entrapped Calcium alginate beads. In vitro drug release in the fed state conditions 
demonstrated sustained release of Acyclovir for 8 h, which best fitted the Higuchi 
model with n < 0.5. Calcium alginate beads containing 20% oil and 2:1 D: P ratio 
showed an optimum DEE (89.54%). Scanning electron microscopy revealed that 
the beads were spherical in shape with rough surface.  
 
21. BrahmaiahBonthagaralaet al.
34
formulated and evaluated extended release 
alginate beads of cefixime. Cefixime alginate beads were prepared by orifice- 
ionotropic gelation methodusing polymers such as HPMC (K 100 M), Carbopol 
940P, Sodium CMC, Guar gum,Sodium Alginate, Ethyl Cellulose, Methyl 
Cellulose and Xanthan gum. Thealginate beads were characterized for drug 
content, entrapment efficiency, mucoadhesiveproperty by in vitro wash-off test 
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and in-vitro drug release. The ideal formulation was selected based on the in-vitro 
release profile which shows anextended drug release of 97.11% upto 8 hours in 
phosphate buffer of pH 7.0. The alginate beads were smooth andelegant in 
appearance showed no visible cracks as confirmed by SEM and FT-IR 
studiesindicated the lack of drug-polymer interactions in the ideal formulation 
(F10).The ideal formulation (F10)followed Higuchi kinetics and value of "n" is 
calculated to be 0.86 indicated that the drugrelease shows non-fickian diffusion. 
 
22. MitraJelvehgarietal.35prepared Chlorpheniramine Maleate-loaded 
Alginate/Chitosan particulate systems by Ionic Gelation method for taste 
masking.The effect of different chitosan and ca2+ concentrations on taste 
masking and the characteristics of the microsphers were investigated. 
Formulations were characterized for particle size and shape, entrapment 
efficiency, FTIR, XRD, DSC, bitter taste threshold and in-vitro drug release 
study.The results of DSC, X-ray diffraction and FTIR showed the presence of 
several CM chemical interactions with alginate and ions (Ca2+ and Al3+). The 
microsphere formulations showed desirable drug entrapment The results of DSC, 
XRD and FTIR showed the presence of several CM chemical interactions with 
alginate and ions (Ca2+ and Al3+). The microsphere formulations showed 
desirable DEE’s(62.2-94.2%). Calcium/aluminum alginate retarded the release of 
CM at low pH = 1.2 and released the drug from microspheres slowly at pH = 6.8, 
simulating intestine pH. 
 
23. Inderbirsinghet al.36formulated and evaluated Domperidone loaded mineral  
oilentrapped emulsion gel  buoyant bead by Emulsion gelation technique. The 
prepared beads were evaluated for particle size, surface morphology, buoyancy, 
actual drug content and entrapment efficiency. Effect of different oils (castor oil, 
olive oil and linseed oil) and oil concentrations (10%, 15% and 20%w/w) on 
uniformity, homogeneity and integrity of the beads was also studied. The results 
of the in-vitrodrug release indicated that linseed oil showed to be good release 
retardant comparedto castor oil and olive oil. Moreover, the beads formulated 
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using 15% w/w linseed oil were more uniform in shape, exhibited maximum 
buoyancy and minimal oil leakage. Diffusion exponent (n) value varied from 
0.4855 to 0.7710 indicating anomalous drug release behavior involving swelling, 
diffusion and/or erosion of the polymer matrix. 
 
24.PeeushSinghalet al.
37
preparaed and evaluated stomach-specific ion tropically 
emulsion gelled alginate beads of Tinidazole. Tinidazole loaded Oil entrapped 
floating beads prepared by the emulsion gelation method were optimized for 
polymer: cross linking agent ratio (sodium alginate/ Calcium chloride),oil 
selection (olive oil and castor oil), oil concentrations (10%, 20% and 30% w/w) 
and drug:polymer (D: P) ratios (1:1, 2:1 and 3:1). The prepared beads were 
evaluated for diameter, surface morphology, encapsulation efficiency, buoyancy 
and in-vitro release. The calcium alginate beads remained buoyant for times in 
excess of 12 h, and the density of the calcium alginate beads was <1.000 g cm. 
The results clearly indicated that the percentage of oil plays an important role in 
controlling the floating of oil-entrapped Calcium alginate beads. In vitro drug 
release demonstrated sustained release of Tinidazole for 8 h, which best fitted the 
Higuchi model with n < 0.5. Calcium alginate beads containing 20% oil and 2:1 
D: P ratio showed an optimum DEE (92.44 %). Scanning electron microscopy 
revealed that externally the calcium alginate beads were spherical in shape, and 
internally, air filled cavities were present thereby enabling floatation of the beads.  
 
25.    Bhatt m b et al.
38
formulated and evaluated ionotropically gelled novel hydrogel 
         beads of valsartan using different ratio of polymer i.e. gellan gum and counter ion  
         like calcium chloride in order to increase the drugbioavailability, therapeutic  
         efficiency, reduce dosing frequency and improvement of patientcompliance. 
         Drug- excipients compatibility was carried out by FTIR. Different formulations 
         were evaluated for particle size, swelling index, % drug entrapment efficiency and 
         in-vitro drug release. Optimized batch was evaluated for SEM.In-vitro release 
         data was fitted to various models to ascertain the kinetic of drug release.A 32 
         factorial was applied to check the effect of varying the concentration of gellan gum 
REVIEW OF LITERATURE 
 
Department of Pharmaceutics, Madras Medical College. Page 32 
 
          (X1) and calcium chloride (X2) on the dependent variable i.e. swelling index and 
in-vitro drug release. It was observed that optimized batch containing gellan 
gum(2.5%) and calcium chloride (4%) gives 123 % swelling index after 12 hrs 
and 100.56 % drugrelease after 24 hrs. 
 
26. Arunkumar Bet al.39formulated and evaluated gastro retentive floating 
microbeads of sumatriptan. The aim was to develop gastro retentive floating 
microbeads which improve the absolute bioavailability of Sumatriptan by 
avoiding the presystemic metabolism and thereby to reduce the dose frequency. 
Drug and polymer compatibility was studied by FTIR spectrophotometry, 
capability of floating in the gastric condition was evaluated. The beads were 
prepared by Ionotropic gelation methodusing Sodium alginate, HPMC K4M and 
Guar gum grade in 1:1, 1:2, 1:3 ratios. The beads were evaluated for percent drug 
entrapment efficiency, and in-vitro drug release. The in-vitro drug release study of 
the beads was carried out in simulated gastric media by USP dissolution method. 
Beads formulated employing Sodium alginate alone could not sustain the drug 
release, whereas beads formulated with mixture of Sodium alginate and 
copolymers demonstrated sustained release of Sumatriptan for 12h. 
 
27. BehinSundara Raj et al.40formulated and evaluated chitosan Prazosin beads by 
Ionotropic gelation method. Prazosin loaded chitosan polyelectrolyte complex 
(PEC) hydrogel beads were prepared via ionotropic gelation and ionotropic 
crosslinking with sodium tripolyphosphate (TPP). A combination of Eudragit 
polymer was studied with chitosan having Prazosin dispersed within them. Thus, 
prazosin dispersed in 2% glacial acetic acid and having chitosan and polymer 
dispersed within. It was cross linked with 2% sodium tripolyphosphate solution 
adjusted to a pH of 4.5-6. The beads prepared were examined for the optimal 
stirring conditions and curing time in order to obtain spherical beads. Beads were 
prepared by three different drug: polymer ratios (1:1, 1:1.5, 1:2). Spherical to oval 
beads with varying particle size, weight, drug entrapment efficiency (DEE), and 
sustained release profile were obtained depending on the drug and polymer 
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combination used. The in-vitro dissolution rate profile showed a sustainedrelease 
of the drug from the beads over a 7 hour study period. Prazosin release decreased 
withan increasing concentration of chitosan. 
 
28. Mahmoud M Ahmed et al.41reported on Emulsification/internal gelation as a 
method for preparation of diclofenac sodium–sodium alginate microparticles as 
controlled release microparticles that might be administered once or twice daily. 
This could be achieved by applying Box-Behnken design to choose these 
formulae. Box-Behnken design determined fifteen formulae containing specified 
amounts of the independent variables, which included stirring speed in rpm (X1), 
drug:polymer ratio (X2) and the surfactant span 80% (X3). The dependent 
variables studied were cumulative percent release after two hours (Y1), four hours 
(Y2) and eight hours (Y3). The prepared microparticles were characterized for 
their production yield, sizes, shapes and morphology, entrapment efficiency and 
Diclofenac sodium in vitro release as well. The formulated microparticles 
exhibited acceptable drug content values that lie in the range 66.20–96.36%. Also, 
the data obtained revealed that increasing the mixing speed (X1) generally 
resulted in decreased microparticle size. However, by increasing surfactant 
concentration, microspheres’ surfaces become smoother and slightly porous. 
Kinetic treatment of the in vitro release from drug-loaded microparticles indicated 
that the zero order is the drug release mechanism for the most formulae. 
 
29. Baljit Singh et al.42developed Gastro retentive floating sterculia–alginate beads 
for use inantiulcer drug delivery by Ionotropic gelation using CaCl2 as 
crosslinker. The beads thus formed were characterized by SEM, electron 
dispersion X-ray analysis (EDAX), FTIR spectroscopy. The swelling of beads has 
been carried out as a function of various reaction parameters and pH of the 
swelling media. In addition, in-vitro release dynamics of anti-ulcer model drug 
Pantoprazole from drug loaded beads in different release media has been carried 
out for the evaluation of the drug release mechanism and diffusion coefficients. 
Release of drug from beads occurred through Fickian type diffusion mechanism. 
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30. Asha patel et al.
43
reported on in-vitro evaluation and optimization of controlled 
release floating drug delivery system of Metformin hydrochloride.In the present 
study, preparation of Metformin hydrochloride floatingmicrospheres, evaluation 
of FDDSin-vitro, prediction of the release,and optimization of floatation and drug 
release pattern to match target release profile was investigated.Floating 
microspheres were prepared by non-aqueous emulsification solvent evaporation 
techniqueusing Ethylcellulose as the rate controlling polymer and 250 mg of 
Metformin hydrochloride per batchand itsin vitro performance was evaluated by 
the usual pharmacopoeial and other tests such as drugpolymercompatibility (FTIR 
scan), yield (%), particle size analysis, drug entrapment efficiency, 
surfacetopography, and in vitro floatation and release studies. Results showed that 
the mixing ratio ofcomponents in the organic phase affected the size, size 
distribution (250-1000 μm), drug content(61 – 134% of theoretical load), yield 
(58– 87%) and drug release of microspheres (47 – 87% after 8 h),floating time (> 
8 hr) and the best results were obtained at the ratio of drug: polymer: 
solvent(250:750:12 and 250:146.45:9 [mg: mg: ml]). 
 
31. Fursule RA et al.44 reported on Study of Multiparticulate Floating drug delivery 
system prepared by Emulsion gelation technique utilizing Amoxicillin trihydrate 
as the model drug. Different formulations of oil entrapped floating gel beads were 
prepared using sodium alginate as gelling agent. The prepared beads were 
evaluated for diameter, surface morphology and encapsulation efficiency. Greater 
percentage buoyancy and highest mean diameter was observed. Highest drug 
loading and SEM results showed that the beads are spherical in shape with rough 
surface and the in-vitro release study revealed that the beads showed sustained 
action for 12 h. 
 
32. Gattani Y S et al.45formulated and evaluated gastro retentive multiparticulate 
drug delivery system of Aceclofenac by the emulsification solvent-evaporation 
technique consisting of Eudragit RS 100 as a polymer. The shape and surface 
morphology of prepared microsphere were characterized by optical and SEM. In-
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vitro drug release studies were performed and drug release kinetics was evaluated 
using the linear regression method. Effects of polymer concentration, stirring rate 
during preparation and effect of temperature on size and drug release was 
evaluated. The prepared microspheres exhibited prolonged drug release (> 12h) 
and remained buoyant for > 12 h. In-vitro studies demonstrated diffusion 
controlled drug release from the microspheres. 
 
33. Pande AV et al.46reported on floating microspheres of Cefpodoxime proxetil: 
formulation and optimization by factorial design. The microspheres were prepared 
by solvent evaporation (o/w emulsion) method using Eudragit S100. A 32 full 
factorial design has been applied. The variables conc. of ES100 and stirring speed 
was studied at three levels and arranged in 32 factorial design to study their 
influence on percentage drug release, percentage entrapment efficiency, and 
particle size. The physical characteristics of floating microspheres were evaluated 
using FTIR, DSC and SEM. 
 
34. Swathi S et al.47reported on formulation and in vitro evaluation of floating 
microspheres of Atomoxetine Hcl. The floating microspheres were prepared by 
using bio compatible polymers like ethyl cellulose along with the drug in different 
proportions by Non-aqueous solvent evaporation method. The microspheres were 
characterized for micromeritic properties, percentage entrapment efficiency, 
percentage yield, Mean particle size, in-vitro buoyancy, in-vitro drug release 
studies. It was observed the increase in concentration of ethyl cellulose increases 
the entrapment efficiency and particle size of the microspheres. In-vitro drug 
release studies showed that release from microsphere get successfully retarded for 
12 h. 
 
35. Rakesh Pahwaet al.48 formulated and evaluated of Floating Multiparticulate 
Drug Delivery System of Glipizide. Floating microspheres were prepared by 
Ionotropic gelation method using polymeric material such as chitosan. D-optimal 
design was utilized to investigate the joint influence of two variables: drug to 
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polymer ratio (X1) and concentration of effervescent agent (X2) on the drug 
entrapment efficiency, percentage buoyancy and cumulative percentage drug 
release. Particle size and surface morphology of prepared microspheres were 
characterized by optical and scanning electron microscopy respectively. 
Formulated microspheres exhibited prolonged drug release and remained buoyant 
for more than12 h. 
 
36. Keyur S Patel et al.49prepared and evaluated chitosan microspheres containing 
nicorandil to reduce the dosing frequency. The nicorandil-loaded chitosan 
microspheres were formulated by emulsion crosslinking method. A 32 factorial 
design was employed to study the influence of drug: Polymer ratio and volume of 
glutaraldehyde on percentage entrapment efficiency, particle size, and % drug 
release at 8 h. The entrapment efficiency was found to be 41.67 ± 1.43-77.33 ± 
1.97% and particle size range 65.67 ± 2.08-146.67± 2.18 μm. The batch CH5 
showed 79.11 ± 2.23 and 96.21 ± 2.41% drug release at 8 and 12 h, respectively. 
Drug: Polymer ratio and volume of GA had significant effect on % entrapment 
efficiency, particle size, and % drug release. From the SEM study observed that 
microspheres were spherical and fairly smooth surface. Fickian diffusion was the 
mode of drug release from Nicorandil-loaded chitosan microspheres. 
 
37. Keyur S Patelet al.50formulated and evaluated  Eudragit Microspheres 
Containing Nicorandil using Eudragit RS 100 and Eudragit RL 100. The Nicorandil 
loaded Eudragit microspheres were formulated by non aqueous solvent evaporation 
method and study the effect of different grade of Eudragit and drug: polymer ratio on 
% Yield, % Entrapment efficiency, particle size and % drug release of microspheres. 
The Entrapment efficiency was found to be 82.31 ± 1.58% to 91.25 ± 2.54% and 
particle size range 60.25 ± 1.42μm to 92.21 ± 2.32μm. The Batch EU6 showed 
almost 100 % drug release at 12 hrs. % In vitro drug release was decreased with 
increasing the drug: polymer ratio. Drug release was high in Eudragit RL 100 
microspheres compare to Eudragit RS 100 microspheres. Fickian diffusion was the 
mode of drug release from Nicorandil loaded Eudragit microspheres. 
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38. Ju-Young Kim et al.51designed and evaluated  Nicorandil Extended-release 
tablet. The in vitro/in vivo relationship of the extended-release formulation was 
confirmed using in vitro dissolution profiles and plasma concentrations of drug in 
beagle dogs. Nicorandil was released completely within 30 min from the 
immediate-release tablets and released for 24 h from the extended-release tablets. 
The Nicorandil plasma concentration could be modified by adjusting the drug 
release rate from the extended-release formulation. The release rate of nicorandil 
was the rate-limiting step in the overall absorption of drug from the extended 
release formulations. These results highlight the potential of a nicorandil 
extended-release formulation in the treatment of angina pectoris. 
 
39. Abdul Baquee Ahmed et al.52reported on drug- excipients compatibility studies 
of Nicorandil in controlled release floating tablet.DSC, Isothermal stress testing 
(IST) and with the support of Fourier transform infrared spectroscopy (FT-IR) 
were used to evaluate compatibility of drug-excipients mixture. The optimized 
formulation developed using the compatible excipients were evaluated for 3 
months of stability studies at 2-8°C and 25°C/60% RH.The results of DSC, IST 
and FT-IR studies confirmed the absence of incompatibility of Nicorandil with 
the excipients used in the formulations. The result of stability studies shows that 
the formulations ware more stable at refrigerator (2-8°C) than stored at 
25°C/60%RH. Besides, the selection of proper excipients storage condition will 
also plays an important role in development of stable dosage form for Nicorandil. 
 
40. Swati Chaturvediet al.54reported on Comparison of Emulsification and Ionic 
Gelation Method of Preparation of Mucoadhesive Microsphere. The purpose of 
this study was to prepare and characterize microspheres loaded by Aceclofenac. 
To achieve this goal Chitosan and Sodium alginate microspheres loaded by 
Aceclofenac were prepared by emulsification and ionic gelation methods. 
Morphology, size, encapsulation efficiency and drug release from these 
microspheres were       evaluated. Microscopic evaluation of microspheres showed 
that microspheres  were spherical in shape. The size analysis results indicated that 
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size range varied from 1 to 13 μm. Encapsulation efficiency of microspheres was 
increased by  increasing drug to polymer ratio. Drug release was found to be Zero 
order.  
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AIM OF THE WORK 
 The main objective of the present study is to develop Capsules containing 
Nicorandil loaded oil entrapped floating alginate beads for the treatment of 
Angina pectoris. 
 The floating beads have been employed to make a sustained release of the drug in 
the stomach to enhance bioavailability and to decrease dose dumping and hence 
overcome its side effects. 
 To optimize the Nicorandil loaded oil-entrapped floating alginate beads by 
Emulsion Gelation method with various Sodium Alginate concentration (2%w/v, 
3%w/v, 4%w/v), Drug:Polymer ratio(1:0.5,1:1,1:2) and various oil concentration  
15%v/v,20%v/v. 
 To capsulate and evaluate the optimized batch of  Nicorandil loaded oil entrapped 
floating alginate beads. 
PLAN OF WORK 
 Preformulation studies. 
 Compatibility studies 
 Construction of Calibration curve. 
 Formulation of Nicorandil loaded oil entrapped floating alginate beads. 
 Evaluation of Nicorandil loaded oil entrapped floating alginate beads. 
 Percentage yield 
 Study of size and Morphology of Alginate beads. 
 Percentage Entrapment Efficiency and Drug Loading. 
 Density of beads. 
 Swelling studies. 
 In-vitro floating properties. 
 In-vitro drug release studies. 
 Preformulation studies for Capsules. 
 Bulk density. 
 Tapped density. 
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 Angle of repose. 
 Carr’s index. 
 Hausner’s ratio. 
 Capsulation of the optimized Nicorandil loaded oil entrapped floating alginate 
beads. 
 Evaluation of Capsules. 
 Uniformity of weight. 
 Disintegration time. 
 In-vitro drug release studies. 
 Similarity factor 
 Evaluation of release kinetics. 
 Stability studies. 
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RATIONALE FOR SELECTION OF NICORANDIL 
52,55,63
 
 Nicorandil is used therapeutically in the long term treatment of Angina pectoris.  
 Nicorandil is primarily absorbed from the upper GI tract and  has a elimination 
half life of 1 hour and it is administered orally as 5-20 mg twice daily (usual dose) 
in order to maintain the constant plasma level. 
 The drug has better solubility in acidic medium. An increase in gastric retention 
time may increase the extent of absorption of the drug. It is more suitable to 
formulate as floating systems for achieving regular and constant plasma levels. 
 Nicorandil is believed to exert myocardial protection by a process of ischaemic   
preconditioning which appears to reduce myocardial stunning, arrhythmias and 
infarct size when a coronary artery is suddenly blocked in addition to 
vasodilatation which is lacked by other vasodilators. Hence, Nicorandil is 
preferred over other vasodilators. 
RATIONALE FOR SELECTION OF DOSAGE FORM
1,4,9,14,15,16
 
 Gastro retentive dosage forms have been developed to improve the clinical 
efficacy of the drug having short half life as well as to improve the patient 
compliance. 
 Single unit formulations are associated with problems such as sticking together or 
being obstructed in gastrointestinal tract, which may have a potential danger of 
producing irritation.  
 Multiple unit systems avoid the ‘all‐or‐none’ gastric emptying nature of single 
unit systems. It reduces the intersubject variability in absorption and the 
probability for dose dumping is lower.  
 Preparation of floating alginate beads is more suitable because it is a 
multiparticulate system, utilizes cheap and non-toxic polymers and there is no use 
any organic solvent. 
 The floating beads have been employed to make a sustained release of the drug in 
the stomach and to decrease the dose of the drug and hence overcome its side 
effects. 
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 Oil entrapped Floating alginate beads is prepared by Emulsion gelation method. 
The entrapped oil aids in the floating of the beads for a prolonged period of time 
within the gastric region. 
 Sodium alginate, a hydrophtilic polymer has been selected since it retards the 
release of the drug from the dosage form (sustained action) and it is 
biodegradable in nature. 
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Angina, also called Angina pectorismeaning ankhon = strangling;pectis = chest - 
is a symptom of an underlying heart condition. It means that the heart is not getting 
enough blood and as a result, not enough oxygen. This decrease of oxygen being 
delivered to the muscle of the heart happens if one or more coronary arteries are 
narrowed or blocked, a condition called atherosclerosis.
56,57
 
This type of blockage may result in chest pain. And while angina does not usually 
damage the heart, and the pain might only last a few minutes, it isa warning sign and it 
should not be ignored.
56 
An angina attack is not the same as a heart attack, although many of the 
symptoms are the same. An angina attack may be provoked by extremes in emotion 
(being very angry or upset), eating a large meal or eating it very quickly, doing more 
exercise than usual (overexerting yourself), being exposed to extremes in temperature 
(too hot or too cold), or smoking. If the angina is a result of physical activity, stopping 
the activity generally stops the pain. But no matter what the cause of the chest pain or 
discomfort, it is important to get  medical attention as soon as possible.
56
 
 
Fig.12: Angina pectoris 
BACKGROUND
58
 
Angina pectoris is the result of myocardial ischemia caused by an imbalance 
between myocardial blood supply and oxygen demand. Angina is a common presenting 
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symptom typically chest pain among patients with coronary artery disease. A 
comprehensive approach to diagnosis and to medical management of angina pectoris is 
an integral part of the daily responsibilities of health care professionals.
 
EPIDEMIOLOGY
59,58
 
As of 2010, angina due to ischemic heart disease affects approximately 112 
million people(1.6% of the population) being slightly more common in men than 
women.(1.7% to 1.5%). 
Angina is more often the presenting symptom of coronary artery disease in 
women than in men. The prevalence of angina rises with increasing age, with a mean age 
of onset of 62.3 years. After five years post-onset, 4.8% of individuals with angina 
subsequently died from Coronary heart disease(CHD). 
 Men with angina were found to have an increased risk of subsequent acute 
myocardial infarction and coronary heart disease related death than women. Similar 
figures apply in the remainder of the western world. As its risk factors are more common 
in western and westernized countries, it could be termed as disease of affluenceThe 
adoption of a rich, westernized diet and subsequent increase of smoking, obesity and 
other risk factors had led to an increase in angina and related diseases in countries such as 
China, India. 
ETIOLOGY AND PATHOPHYSIOLOGY
60,61
 
             Angina pectoris occurs when cardiac workload and resultant myocardial oxygen 
demand exceed the ability of coronary arteries to supply an adequate amount of 
oxygenated blood. This can occur when the arteries are narrowed. Narrowing of arteries 
results from atherosclerosis but may results from coronary artery spasm or rarely, 
coronary artery embolism. Due to myocardium ischemia, the myocardial tissues are 
deprived of oxygen and nutrients for the aerobic metabolism. As aresult there is an 
inclusion of anaerobic metabolism which leads to accumulation of lactic acid. 
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Due to increase of lactic acid, myocardial nerve fibres are irritated and this 
transmit a pain message to the cardiac nerves and upper thoracic posterior nerve roots. 
All this leads to cardiac pain, the Angina.  
 
 
Fig.13: Atherosclerosis 
TYPES OF ANGINA
56,59,62
 
Five different kinds of angina have been identified, with the two most common 
being Stable angina and Unstable angina. 
1.  Stable (typical) angina 
 The most common form of angina 
 Consequence of coronary atherosclerosis 
 Presents in physical activity(exercise), emotional stress etc. 
 Predictable, reproducible (exertion) – The pain goes away in few 
minutes once the gets out of the stress or takes medications. 
 Worse in cold conditions and after meals. 
2. Unstable angina (crescendo/pre-infarction angina) 
 Intermediate state between stable angina and MI. 
 A  presentation of “acute coronary syndromes” (ACS). 
 May appear unexpectedly, at rest. 
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 Often not associated with physical activity. 
 Usually a consequence of severe coronaryatherosclerosis possibly 
complicated by arupture and thrombus formation. 
 People with unstable angina are at increased risk for heart attacks, 
cardiac arrest, or severe cardiac arrhythmias (irregular heartbeat or 
abnormal heart rhythm). 
 Management issimilar to that of MI 
3. Prinzmetal angina (variant/vasospastic angina) 
  An uncommon form of angina. 
 Consequence of coronary artery spasm – May cause severe pain. 
  Occurs at rest (Usually between midnight and 8 am in the 
morning). 
 Most people who have variant angina have severe atherosclerosis 
(hardening of the arteries), and the spasm is most likely to occur 
near a buildup of fatty plaque in an artery. 
4. Microvascular angina 
 Referred to as Syndrome X 
 Occurs when tiny vessels in the heart become narrow and stop 
functioning  properly, even if the bigger arteries are not blocked by 
plaque.  
 Treated with common angina medications. 
5. Atypical angina 
 Often doesn’t cause pain, but a vague discomfort in chest can be 
felt 
 Experience shortness of breath, feel tired or nauseous, have 
indigestion, or pain in back or neck.  
 Women are more likely than men to have feelings of vague chest   
discomfort. 
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RISK FACTORS
56
 
 High blood pressure (for more on high blood pressure, click here)  
 Diabetes  
 Unhealthy cholesterol levels  
 Smoking  
 Lack of exercise  
 Obesity  
 Too much salt in diet  
 Excessive use of alcohol  
 Family history of CAD or stroke  
 Male gender 
 Being a postmenopausal woman  
 Age - the risk increases for men over the age of 45 and for women 
over the age of 55. 
SYMPTOMS
56
 
  The symptoms of angina are different for different people, but regardless, they 
are usually experienced after heavy exercise or because of emotional stress.  
  Pain that begins in the middle of your chest and then spreads to 
your left   arm, back, neck or jaw; usually this is not a sharp pain, 
but a dull one  
 A feeling of pressure, tightness or squeezing in your chest or arms  
 A feeling of persistent indigestion that is moderate or severe  
 Numbness, or a lack of feeling in your arms, shoulders or wrists 
 
The symptoms vary according to the type of angina.For example,if  a person has 
stable angina, the pain or discomfort:  
 Happens when the heart has to work harder, during exercise. 
 Is no surprise and feels the same each time it happens. 
 Usually lasts less than 5 minutes, and stops after taking rest or 
medication. 
 It might feel like indigestion. 
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Unstable angina is different. The pain or discomfort:  
  Often happens when while sleeping or resting. 
  Might last as long as 30 minutes and might become progressively 
worse. 
  Cannot be relieved with rest or medication. 
  Might be a sign of a heart attack that will happen soon  
 Unstable angina tends to happen more often in older adults. 
 
 
Fig.14: Representing pain radiation 
 
DIAGNOSIS
58
 
  Diagnostic studies that may be employed include the following: 
A) Chest radiography 
   Usually normal in angina pectoris but may show cardiomegaly in patients with 
previous MI, Ischemic cardiomyopathy, pericardial  effusion or acute pulmonary edema. 
B) Gradedexercise stress testing 
This is the most widely used test for the evaluation of patients presenting with 
chest pain and can be performed alone and in conjugation with echocardiography or 
myocardial perfusion scintigraphy. 
C) Coronary artery calcium (CAC) scoring by fast CT 
The primary fast CT methods for this application are electron-beam CT (EBCT) 
and multidetector CT (MDCT). 
Other tests that may be useful include the following: 
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D) Electrocardiogram(ECG) 
It involves hooking up to a machine that detects and records your heart’s 
electrical activity. This is a painless procedure and does not take very long  
E) Selective coronary angiography 
The definite diagnostic test for evaluating the anatomic extent and severity of 
CAD. 
F) Computed tomography (CT) scan 
It is like a high-speed x-ray and show the amount of calcium present in the 
arteries. The level of calcium help to show whether coronary artery disease prevails. 
 
 If one or more of these tests do show positivity for  angina, the diagnosis might 
be confirmed by undergoing cardiac catheterization. A special dye will be injected into 
the arteries and then photographs taken of them that allows the physician to see whether  
they are narrow. 
 
TREATMENT
58
 
   The main goals of treatment in Angina pectoris are relief of symptoms, slowing 
progression of the disease and reduction of future events, especially heart attacks and 
death.  
Lifestyle modifications 
• Increased, controlled physical activity (exercise training) 
• Smoking cessation 
• Weight management, balanced diet 
Pharmacotherapy
58,63 
Three major drug classes: 
• Organic nitrates 
• CCBs 
• β-blockers 
 Nitrates are available in a number of different forms.Nitroglycerin that can be 
taken under the tongue (called sublingual) or sprayed into the mouth works very 
quickly to relieve the pain of an angina attack, while other forms of nitroglycerin, 
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like tablets or patches, can be taken to help prevent an attack from starting. 
Headache is a possible side effect.  
 Beta-blockers are a class of medicines used to treat several kinds of heart disease. 
They work by lowering blood pressure, and slowing heart rate which means the 
heart doesn’t have to work as hard.  
 Calcium channel blockers or calcium antagonists also work by lowering blood 
pressure and slowing heart rate, and are often used if you cannot take a beta-
blocker. They may be useful to treat coronary artery spasm.  
 Antiplatelet medications are blood thinners that work by preventing blood clots 
from forming and blocking your arteries. The most commonly used antiplatelet 
medication is aspirin, which works by preventing platelets from sticking to blood 
vessel walls. An enteric-coated aspirin is generally recommended because it is 
easier on the stomach. Other medications can be used to stop platelets from 
sticking together. They may be used to reduce the risk of clot-induced heart 
attacks or strokes. 
 Other medications that might be helpful in angina includes  
 Cholesterol-lowering drugs known as statins can help to reduce the chance of a 
heart attack in someone with angina.  
 ACE inhibitors which are used primarily to treat high blood pressure, may 
reduce the chance of heart attack in some people with angina, even if their blood 
pressure is normal. 
 
Surgical procedures 
Treating unstable angina sometimes requires surgical intervention, with or or 
without the previous use of medications. Two procedures are available:  
Angioplasty is a procedure in which a small catheter (a little tube) is inserted into 
a narrowed or blocked artery. At the top of this catheter is a little balloon that the 
physician inflates when the catheter has reached the blocked part of the artery. The 
balloon, when inflated, helps to push the plaque against the wall of the artery. Once the 
balloon is deflated, it often opens up the blockage enough for more blood to flow through 
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the artery, and this should lessen the pain. In some cases, a small device called a stent 
will be put in place to help prop your artery open.  
 
 
 
Fig.15: Angioplasty 
 
If several arteries are severely blocked, coronary artery bypass surgery 
(also sometimes referred to as coronary artery bypass grafting or CABG) may be 
recommended. This procedure involves taking a healthy artery or vein from another place 
in your body (your leg, for example), and grafting it in your heart to help the blood go 
around (or bypass) the blockage. 
 
 
6. DRUG PROFILE 
 
Department of Pharmaceutics, Madras Medical College Page 52 
 
NICORANDIL
63,64,65,66,67,68
 
PHYSIOCHEMICAL PROPERTIES 
Chemical structure:  
 
Chemical Name : N‐[2‐hydroxyethyl] nicotinamide nitrate [ester] 
Molecular Formula: C8H9N3O4 
Molecular Weight : 211.175g/mol 
Description : A white to off- white crystalline powder. 
Melting point : 92ºC -93ºC 
Solubility : Freely soluble in methanol, in acetone and in glacial acetic acid. Soluble in 
dichloromethane. Sparingly soluble in chloroform. 
Density:  1.3g/cm
3
 
CAS Number : 65141-46-0 
MECHANISM OF ACTION  
        Nicorandil activates ATP sensitive K+ channels- hyperpolarize the vascular 
smooth muscle.  
                    Like Nitrates, it also acts as a NO donor – relaxes blood vessels by 
increasing cGMP. Thus, arterial dilatation is coupled with venodilatation. Coronary flow 
is increased and dilates bothepicardial conducting vessels and deeper resistance vessels. 
No significant cardiac effects on contractility and conduction are noted. 
                    Mitochondrial k
+
 ATP channel opening by Nicorandil is believed to exert 
myocardial protection by a process of ischaemic preconditioning which appears to reduce 
myocardial stunning, arrhythmias and infarct size when a coronary artery is suddenly 
blocked.  
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PHARMACOKINETICS 
Absorption 
Nicorandil is well absorbed from the gastrointestinal tract and maximum plasma 
concentration of nicorandil is linearly related to the administered dose. The urinary 
recovery data following oral administration of the drug indicated that more than 90% of 
the oral dose (20 mg) was absorbed. There is some evidence that consumption of food 
concurrently with the administration of Nicorandil can prolong drug absorption resulting 
in a delayed and decreased maximum plasma concentration.  
Bioavailability 
The absolute bioavailability of Nicorandil is75±23%, indicating that no 
significant first pass effect exists. 
Half‐ life  
1 hour 
Distribution 
After oral (and i.v.) administration of the drug, the apparent volume of 
distribution is approximately 1.0 L/kg body weight. The drug distribution in the body was 
reported that it follows two compartment model. It is very weakly bound to albumin 
(19.4%) and protein binding is found to be (23.3 %). 
Metabolism 
Nicorandil is metabolized extensively and the nicotinamide/nicotinic acid 
biotransformation pathway contributes to the accumulation of Nicorandil and 
2‐nicotinamidoethanol (denitrated metabolite)during repeated dosing because of the 
saturable merging of nicotinamide/nicotinic acid derivatives (from the Nicorandil  
metabolism) into the NAD/NADP endogenous pool of coenzymes. After metabolism the 
Nicorandil is converted primarily to the denitrated compound, SG‐86 (N‐2‐hydroxyethyl 
nicotinamide), which is pharmacologically inactive. 
Excretion 
             The major route of elimination is through kidney: Less than 2% of the dose is 
excreted through the biliary route. The total body clearance of Nicorandil is equal to 52 ± 
18lit/hr, indicating that it is less than the liver blood flow. 
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THERAPEUTIC INDICATION  
 Angina pectoris  
 Hypertension 
ROUTE AND DOSAGE  
Adult : Oral :  
 Initial dose - 10mg twice daily. 
 Usual dose – 10-20mg twice daily. 
 Maximum dose – 30mg twice daily. 
CONTRAINDICATIONS 
Contraindicated in patients with cardiogenic shock (poor blood circulation), heart 
failure, low blood pressure breast-feeding and children. 
SIDE EFFECTS  
 Most common – Headache, dizziness, drowsiness, nausea, vomiting, flushing, 
weakness and rectal bleeding. 
 Heart – Fast heart rate and low blood pressure. 
 Miscellaneous – Rash, abnormal liver function, mouth ulcer and muscle pain. 
MARKETED FORMULATIONS 
 K- COR 
 KORANDIL 
 NIKORAN 
 NICODUCE 
 ZYNICOR 
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SODIUM ALGINATE
69
 
1. Nonproprietary Names: 
                           BP: Sodium alginate, PhEur: Natrii alginas, USPNF: Sodium alginate 
2. Synonyms: 
                          Algin, alginic acid, sodium salt, E401, Kelcosol, Keltone, Protanal,  
      sodium, Polymannuronate.         
3. Chemical Name: 
              Sodium alginate  
4. Empirical Formula and Molecular Weight: 
                          Sodium alginate consists chiefly of the sodium salt of alginic 
      acid, which is a mixture of polyuronic acids composed of residues of D-mannuronic     
      acid and L-guluronic acid. 
5. Functional Category: 
                           Stabilizing agent, suspending agent, tablet and capsule disintegrant,  
      tablet binder, viscosity-increasing agent 
6. Description: 
                           Sodium alginate occurs as an odorless and tasteless, white to pale  
       yellowish brown colored powder.  
7. Solubility: 
              Practically insoluble in ethanol (95%), ether, chloroform, ethanol/water  
       mixtures in which the ethanol content is greater than 30%. Also, practically insoluble     
       in other organic solvents and aqueous acidic solutions in which the pH is less than 3.  
       Slowly soluble in water forming a viscous colloidal solution. 
8. Applications : 
 Sodium alginate is used in a variety of oral and topical pharmaceutical        
formulations. In tablet formulations, sodium alginate may be used as both a binder(1-       
3%) and disintegrant(2.5-10%). It has been used as a diluent in capsule formulations.      
Sodium alginate has also been used in the preparation of sustained release  oral       
formulations since it can delay the dissolution of a drug from tablets, capsules and        
aqueous suspensions. 
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   In topical formulations, sodium alginate is widely used as a thickening and 
suspending agent (1-5%) in a variety of pastes, creams and gels, and as a stabilizing 
agent (1-3%) for oil-in-water emulsions. It  has been used for the aqueous 
microencapsulation of drugs, in contrast with the more conventional 
microencapsulation techniques which use organic-solvent systems. It has also been 
used in the formation of nanoparticles. Sponges composed of sodium alginate and 
chitosan produce a sustained drug release 
           Other novel delivery systems containing sodium alginate include   ophthalmic 
solutions that form a gel in situ when administered to the eye; an in situ   forming gel 
containing Paracetamol for oral administration; and a freeze-dried device   
intended for the delivery of bone growth factors. Hydrogel systems containing     
alginate  have also been investigated for delivery of proteins and peptides. 
         Alginate dressings, used to treat exuding wounds, often contain significant 
amounts of sodium alginate as this improves the gelling properties.   
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HYDROXY PROPYL METHYL CELLULOSE
69
 
1.  Non-proprietary Name: 
                 BP: Hypromellose, JP: Hypromellose PhEur: Hypromellose  
    USP: Hypromellose 
2.  Synonyms: 
                 Benecel MHPC, E464, hydroxyl propyl methyl cellulose, HPMC 
     Hypromellosum, methocel, methyl cellulose propylene glycol ether, methyl hydroxyl 
     propyl cellulose, metolose, MHPC, Pharmacoat, Tylophor, Tylose 
3.  Chemical Name: 
                Cellulose hydroxyl propyl methyl ether 
4.  Molecular weight: 
                Molecular weight approximately 10000-1500000 
5.  Functional category: 
                Bio adhesive material, coating agent, controlled release agent, emulsifying   
     agent, film forming agent, suspending agent, sustained release agent, tablet binder. 
6.  Description: 
                Hypromellose is an odourless and tasteless, white or creamy – white fibrous or 
    granular powder. 
7.  Solubility : 
                Soluble in cold water, forming a viscous colloidal solution; practically     
    insoluble in  hot water, chloroform, ethanol (95%) and ether. 
8.  Applications: 
                HPMC is widely used in oral, ophthalmic, nasal and topical pharmaceutical      
formulations. It is used as tablet binder in film-coating and as a matrix for extended      
release tablet formulations, concentrations between 2-5% used as binder in either wet      
or dry granulation processes. High viscosity grades may be used to retard the release 
of drugs from a matrix at levels of 10-80%w/w in tablets and capsules. Hypromellose 
is also used in liquid oral dosage forms as a suspending and/or thickening agent at     
concentrations ranging from 0.25-5.0%. 
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CALCIUM CHLORIDE
64,70,71 
1.  IUPAC Name: 
                  Calcium chloride 
2.  Other Names: 
               Calcium(II) chloride, Calcium dichloride, E509 
3. Molecular formula: 
                Cacl2 
4.  Molecular weight: 
                110.984g/mol 
5.  Description: 
                White powder, Hygroscopic and odorless. 
6. Density: 
                2.15 g/cm
3  
 
7. Melting point: 
               772-775 ºC (anhydrous) 
8. Boiling point: 
               1,935 ºC (anhydrous) 
9.  Solubility : 
                 Highly soluble in water (74.5g/100ml - 20 ºC) 
10.  Applications: 
 Desiccant 
 Used as a cross-linking agent in the preparation of pharmaceutical 
formulations  
 Used to quickly treat calcium channel blocker toxicity 
  It is injected to treat internal hydrofluoric acid burns. 
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                                             MINERAL OIL, LIGHT
69
 
1.  Nonproprietary Names 
                          BP: Liquid paraffin ; JP: Liquid paraffin; PhEur: Paraffinum liquidum 
             USP: Mineral oil 
2.  Synonyms 
                          905 (mineral hydrocarbons); Citation; light liquid petrolatum; 
light white mineral oil. 
3. Chemical Name 
                         Mineral oil  
     4. Empirical Formula and Molecular Weight 
                         Light mineral oil is a mixture of refined liquid saturated hydrocarbons   
         obtained from petroleum. It is less viscous and has a lower specific gravity than  
         mineral oil. 
    5. Functional Category 
                         Emollient, tablet and capsule lubricant, oleaginous vehicle, solvent  
         therapeutic agent. 
    6. Description 
                Light mineral oil is a transparent, colorless liquid, without fluorescence in  
daylight. It is practically tasteless and odorless when cold, and has a faint odor 
when  heated. The USPNF 23 specifies that light mineral oil may contain a suitable 
stabilizer. 
    7. Solubility 
                  Practically insoluble in ethanol (95%), glycerin, and water; soluble in 
acetone, benzene, chloroform, carbon disulfide, ether, and petroleum ether. 
miscible  with volatile oils and fixed oils, with the exception of castor oil. 
    8. Applications 
                            Light mineral oil is used in applications similar to those of mineral oil. 
It is used primarily as an excipient in topical pharmaceutical formulations where its 
emollient properties are exploited in ointment bases(0.2-23%). It is also used in 
ophthalmic formulations(< 15%). Light mineral oil is additionally used in oil-in-
water and polyethlylene glycol/gylcerol emulsions, as a solvent and lubricant in 
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capsules  and tablets, as a solvent and penetration enhancer in transdermal 
preparations and as  the oily medium used in the microencapsulation of many 
drugs. Light mineral oil is  also used in cosmetics and certain food products. 
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MAGNESIUM STEARATE
69
 
1.  Non-proprietary names: 
BP:Magnesium stearate, JP: magnesium stearate, PhEur:magnesium 
stearate,   USP- NF: Magnesium stearate. 
2.  Synonyms: 
                             Dibasic magnesium stearate, Magnesiudistearate, Magnesia stearas, 
             Magnesium octadecanoate, octadecanoic acid, magnesium salt, Synpro 90. 
      3.    Chemical name: 
                   Octa decanoic acid, Magnesium salt. 
      4.    Empirical formula: 
     C36H70MgO4 
      5.    Molecular weight: 
     591.24 
      6.    Functional category: 
    Tablet and capsule lubricant. 
      7.    Description: 
    Magnesium stearate is a very fine, light white, impalpable powder of 
low bulk density, having a faint odour of stearic acid and a characteristic taste. 
The powder is greasy to the touch and readily adheres to the skin. 
      8.    Incompatibilities: 
    Incompatible with strong acids, alkalis and iron salts. 
      9.    Applications: 
        It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0%w/w. It is hydrophobic and may retard 
the dissolution of a drug from solid dosage form. The lowest possible 
concentration is therefore used in such formulations. 
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MATERIALS USED IN FORMULATION 
Table 3: List of materials and their applications in the formulation 
 
S.No. 
 
 
Name of the material 
 
Manufacturer/Supplier 
 
Applications 
 
1. 
 
Nicorandil 
 
Madras Pharmaceuticals 
Ltd. 
 
 
Active ingredient 
 
2. 
 
Sodium alginate 
 
Macleods 
Pharmaceuticals Ltd. 
 
 
Hydrophilic Polymer 
 
3. 
 
 
HPMC K 100M 
 
Kniss Laboratories 
 
Hydrophilic polymer 
 
4. 
 
Liquid paraffin 
 
Lab Chemicals 
 
 
Oil phase 
 
 5. 
 
 
Calcium chloride 
 
Lab Chemicals 
 
Cross-linking agent 
 
6. 
 
Magnesium stearate 
 
 
Kniss Laborataries 
 
Lubricant 
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EQUIPMENTS/INSTRUMENTS USED IN FORMULATION 
Table 4: List of equipments/instruments used 
 
S.No. 
 
 
Equipment’s / Instruments 
 
Manufacturer / Supplier 
 
1. 
 
Electronic weighing balance 
 
 
Asha scientific company, Mumbai 
 
2. 
 
Magnetic stirrer 
 
 
REMI 1MLH 
 
3. 
 
pH meter 
 
 
MC Dalal, Chennai 
 
4. 
 
Disintegration apparatus 
 
 
Electrolab, India 
 
5. 
 
Dissolution tester 
 
 
Campbell Electronics, India 
 
6. 
 
UV-visible spectrophotometer 
 
 
Shimadzu, Japan 
 
7. 
 
Fourier Transform Infra-Red 
Spectrophotometer 
 
 
Nicolet, India 
 
8. 
 
Scanning Electron Microscopy 
 
 
Hitachi, Japan 
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METHODOLOGY 
PREFORMULATION STUDIES: 
The Preformulation studies are conducted to establish the physiochemical 
characteristics of the drug and its compatibility with the various excipients. The 
Preformulation studies are necessary to formulate drug into stable, safe and effective 
dosage form. 
 
DRUG EXCIPIENT COMPATIBILITY STUDY
72
 
The drug and the excipients chosen for the formulation were screened for 
compatibility by physical methods and Fourier Transform Infrared (FTIR) spectroscopic 
studies.. 
 Compatibility study by FTIR 
Infrared spectroscopy can be used to identify a compound and also to investigate 
the composition of the mixture. Pure drugs, polymers, excipients and drug excipient 
mixture were subjected to FTIR studies to investigate the Drug- excipient interactions. 
The IR spectra of the test samples were obtained by Pressed Pellet Technique using 
Potassium bromide. 
Potassium bromide pellet method: 
A small amount of finely ground solid samples intimately mixed with about 
100times its weight of powdered potassium bromide. The finely ground mixture was then 
passed under very high pressure in a press (atleast 25,000 psig) to form a small 
pellet(about 1-2 mm thick and 1 cm in diameter). The resulting pellet was transparent to 
IR radiation and was run as such. 
 
PREPARATION OF BUFFER SOLUTIONS 
A. Preparation of 0.1N (pH 1.2) Hydrochloric Acid
64
 
8.5ml of the hydrochloric acid was dissolved in water and made upto 1000 ml to 
get0.1N hydrochloric acid. 
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CALIBRATION CURVE
49,50
 
For Nicorandil 
100 mg of  Nicorandil drug was transferred to a 100 ml standard flask and made 
upto volume with 0.1N HCl. 10 ml was pipetted out into separate 100 ml flask and made 
upto volume with 0.1N HCl. 2ml,4ml, 6ml,8ml and10ml were taken and made upto 
100ml using 0.1N HCl. The absorbance of the resulting solutions was measured at 262nm 
using UV spectrophotometer. The Calibration curve was then plotted. 
 
FORMULATION DEVELOPMENT
14,15,16
 
Formulation of Nicorandil loaded Oil entrapped floating alginate beads 
The Nicorandil loaded oil entrapped Floating Alginate beads was formulated by 
Emulsion Gelation method. In this method sodium alginate solution (2%w/v, 3%w/v, 
4%w/v) containing floating polymer HPMC K100M(0.5% w/v) was prepared.Liquid 
paraffin in the concentration 15%v/v and 20% v/v was then added with high shear 
mixing. Nicorandil was then dispersed in the formed emulsion in fixed Drug: Alginate 
ratio(1:0.5, 1:1,1:2). This mixture was extruded, using syringe G 24 needle into 5% w/v 
calcium chloride solution. The gel beads were allowed to stand in solution for 30 minutes 
with mild stirring before being separated and dried.  Floating Alginate beads were 
formulated by varying the Sodium Alginate concentration (2%w/v,3%w/v, 4% w/v) 
Drug:Polymer ratio(1:0.5,1:2,1:1) and oil concentration(15%v/v, 20% v/v). 
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FLOW CHART FOR FORMULATION OF NICORANDIL LOADED OIL  
ENTRAPPED FLOATING ALGINATE BEADS 
EMULSION GELATION METHOD 
Sodium Alginate + Distilled water 
↓(Dissolve) 
Add HPMC K 100M 
↓ 
Add Liquid paraffin(Mineral oil) 
                              ↓(High shear mixing) 
Drug is Dispersed 
↓ 
Mixture Extruded using 24 gauge needle into 5% Calcium chloride solution 
↓ 
Gel beads allowed to stand in solution for 30 minutes (curing time) 
↓ 
Washed and Dried 
                                                                      ↓(Optimized batch+ Magnesium stearate-5%) 
Capsulated in a Hard gelatin capsule (20mg equivalent) 
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         Table5: Formulation table for Nicorandil loaded oil entrapped floating alginate beads 
 
Formula 
No. 
 
 
Drug:Alginate 
ratio 
 
Sodium alginate 
concentration 
%w/v 
 
 
HPMC K100M 
%w/v 
 
Mineral oil 
%v/v 
1. 1:0.5 2 0.5 15 
2. 1:0.5 2 0.5 20 
3. 1:2 2 0.5 15 
4. 1:2 2 0.5 20 
5. 1:1 2 0.5 15 
6. 1:1 2 0.5 20 
7. 1:2 3 0.5 15 
8. 1:2 3 0.5 20 
9. 1:1 3 0.5 15 
10. 1:1 3 0.5 20 
11. 1:2 4 0.5 15 
12. 1:2 4 0.5 20 
13. 1:1 4 0.5 15 
14. 1:1 4 0.5 20 
 
EVALATION OF NICORANDIL LOADED OIL ENTRAPPED FLOATING ALGINATE 
BEADS 
1. STUDY OF SIZE AND MORPHOLOGY OF  BEADS15,17 
The diameter of beads was determined by screw gauge. For this  
purpose, 20 dried beads were randomly selected from each batch and the mean diameter 
was determined by screw gauge. The least count of screw gauge was 0.005 mm. Surface 
and cross-sectional morphologies of beads were examined with a Scanning Electron 
Microscope. 
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2. PERCENTAGE YIELD 
The percentage yield for the different formulations were calculated using  
 the formula      
               Percentage yield = Practical yield / Theoritical yield × 100 
3. DRUG LOADING(DL) AND ENTRAPMENT EFFICIENCY(EE)16 
An accurately weighed sample of beads (100mg) was crushed in a mortar. 
The crushed material was dissolved in 75ml of 0.1N HCl, then made upto 100ml. 
This mixture was filtered and analyzed by UV/visible spectrophotometer at λ max 
262 nm against 0.1N HCl as blank. The drug loading and entrapment efficiency 
percent can be calculated using the following equations. 
           DL% = (Actual drug content/ Weight of beads) × 100 
 
           EE% = (Actual drug content/ Theoretical drug content) × 100 
4. DENSITY OF BEADS16 
                In this method floating beads were transferred to a measuring cylinder, 
tapped manually until constant volume was obtained. This volume is bulk 
volume(i.e.) it’s the true volume of beads and the void space between them. The 
following equation was used to calculate the bulk density. 
Bulk density = Mass of beads / Bulk volume 
5. SWELLING STUDIES15,30 
     Beads were studied for swelling characteristics. Only those batches  
Were selected which have good drug content and entrapment efficiency more than  
50%. Sample from drug-loaded beads were taken, weighed and placed in wire  
basket of USP Dissolution apparatus II. The basket containing beads was put in a  
beaker containing  100   ml of 0.1 N HCl (pH 1.2) maintained at 37
0
C. The beads 
were periodically removed  at predetermined intervals and weighed. Then the  
swelling ratio was calculated as per the following formula: 
                             Swelling ratio = Weight of wet beads/ Weight of dried beads 
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6. IN-VITRO FLOATING PROPERTIES15,16 
The Nicorandil loaded oil entrapped floating alginate beads were  
immersed in 900 ml of 0.1N HCl (pH 1.2) in USP type II apparatus at 50 rpm 
maintained at37 ± 5◦C . The floating ability (buoyancy) of beads was measured by  
visual observation. The time taken to float at the surface of dissolution medium  
(known as floating lag-time) and duration of floating were noted. 
7. IN-VITRORELEASE STUDY30,49,50 
The dissolution rate of the prepared beads was studied using USP  
rotating paddle dissolution apparatus II. Known weight of beads containing  
equivalent amount of   20 mg of Nicorandil was placed in the dissolution medium 
(900 ml of buffer pH 1.2). The temperature was adjusted to 37 ±0.5 
0
C at 50 rpm.  
5 ml of samples was withdrawn atspecified time intervals (1 hr) and replaced with  
fresh dissolution medium. The quantity of the drug released was determined using  
spectrophotometrically at 262 nm. The release rate of 20 mg of Nicorandil was 
determined.The experiment was carried out in triplicate and the average values of  
the released amount were calculated and plotted versus timeThe results were  
expressed as the percentage ofcumulative amount released as a functionof time. 
 
PREFORMULATION STUDIES FOR CAPSULES: 
FLOW PROPERTY MEASUREMENTS
64,73
 
The flow properties of powers/beads are critical for an efficient  
Capsule filling operation. A good flow of the sample to be filled is necessary to assure  
efficient mixing and acceptable weight uniformity for the filled capsule. The flow  
property measurements include bulk density, tapped density, angle of repose,  
compressibility index and Hausner’s ratio. The flow property measurements of the  
beads were determined. 
a) BULK DENSITY (ρb)73 
It is the ratio of total mass of beads to the bulk volume of beads. It  
was measured by pouring the weighed beads into a measuring cylinder and initial  
weight was noted. This initial volume was called the bulk volume. From this the  
bulk density was calculated according to the formula mentioned below. It is  
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expressed in g/ml and is given by 
ρb = M/ Vb 
   Where, M and Vbare mass of powder and bulk volume of the beads respectively. 
b) TAPPED DENSITY(ρt)73 
It is the ratio of weight of the  beads to the tapped volume of beads.  
The beads was introduced into a measuring cylinder with the aid of funnel and  
tapped for500 times on a wooden surface at a 2 sec interval and the volume  
attained is the tapped volume. It is expressed in g/ml and is given by 
ρt = M / Vt 
  Where, M and Vtare mass and tapped volume of the beads respectively. 
c) ANGLE OF REPOSE (θ)73 
The flow properties were characterized in terms of angle of repose,  
Carr’s Index and Hausner’s ratio. For determination of angle of repose (θ), the beads  
Were poured through the walls of a funnel, which was fixed at a position such that its  
lower tip  was at a height of exactly 2.0 cm above hard surface. The beads were  
poured till the time when upper tip of the pile surface touched the lower tip of the  
funnel. Angle of repose was calculated using following equation. 
θ = tan-1(h/r) 
  Where, h = height of pile in cm; r = radius of pile in cm 
d)CARR’S INDEX (OR) % COMPRESSIBILITY73 
It indicates beads flow properties. It was measured for determining  
the relative importance of interparticulate interactions. It is expressed in percentage 
and is given by 
CI = ρt –ρb/ρtX 100 
  Where, ρt and ρb are tapped density and bulk density respectively. 
e) HAUSNER RATIO
73
 
Hausner’s ratio is an indirect index of ease of beads. It was 
calculated bythe following formula. 
HR = ρt / ρb 
  Where, ρt and ρb are tapped density and bulk density respectively. 
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Table6:  Angle of Repose, Compressibility Index and Hausner’s Ratio72 
Flow property Angle of repose Compressibility 
index 
Hausner’s ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >65 >38 >1.60 
 
 
CAPSULATION OF THE OPTIMIZED NICORANDIL LOADED OIL 
ENTRAPPED FLOATING ALGINATE BEADS
14
 
Nicorandil-loaded oil-entrapped beads equivalent to 20 mg of Nicorandil were 
mixed with magnesium stearate (5%, w/w) as lubricating agent for 3 minutes and filled 
into empty hard gelatin capsules (size 1) manually. Care wastaken to fill the contents 
completely to maintain the uniformity of contents and weight. 
Table7: Formulation of capsules 
Formula no. Nicorandil beads 
(equivalent to 0.020 g) 
Magnesium stearate 
 (5%) 
F-5 0.174g 0.0087g 
 
 
EVALUATION OF CAPSULES 
a) UNIFORMITY OF WEIGHT64 
Intact capsules were weighed. The capsules were opened without losing any part 
of the shell and the contents were removed as completely as possible. The shell was 
washed with ether and the shell allowed to stand until the odour of the solvent was no 
longer detectable. The empty shell was weighed. The procedure was repeated with the 
remaining 19 capsules. Determine the average weight. Not more than two of the 
individual weights deviate from the average weight was determined.  
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Table 8: Uniformity of weight 
 
S.No. 
 
Average weight of  
capsule contents 
 
 
  Percentage deviation 
 
1. 
 
Less than 300mg 
 
 
10 
 
2. 
 
300 mg or more 
 
 
7.5 
 
b) DISINTEGRATION
64
 
Randomly six capsules were selected for disintegration test. Disintegration test 
was performed with disc in 0.1N HCl (37 ± 0.5
0
C)using United States Pharmacopeia 
(USP) disintegration apparatus.  
c) IN-VITRO DRUG RELEASE STUDIES
63,14
 
The capsules containing Nicorandil loaded oil-entrapped beads were evaluated for 
their in-vitro drug release and were placed into900 ml of  0.1N HCl (pH 1.2), maintained 
at 37 ± 0.5◦Cand 50 rpm paddle speed in USP type-II dissolution apparatus. 5 ml of 
aliquots was collected at regular selected time intervals, and soon after same amount 
fresh buffer was replaced into dissolution vessel keeping the sink condition throughout 
the experiment. The collected aliquots were analyzed to find out the amount of drug 
release from the beads by using UV–visible spectrophotometer by measuring absorbance 
at λmax of 262 nm. 
IN-VITRO DRUG RELEASE STUDY OF MARKETED FORMULATION
64
 
The Nicorandil prolonged release marketed tablet was evaluated for itsin-vitro 
drug release and were placed into900 ml of  distilled water, maintained at 37 ± 0.5◦Cand 
50 rpm paddle speed in USP type-II dissolution apparatus. 5 ml of aliquots was collected 
at regular selected time intervals, and soon after same amount fresh buffer was replaced 
into dissolution vessel keeping the sink condition throughout the experiment. The 
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collected aliquots were analyzed to find out the amount of drug release from the beads by 
using UV–visible spectrophotometer by measuring absorbance at λmaxof 262 nm. 
EVALUATION OF IN-VITRO RELEASE KINETICS
14,74
 
To study the in-vitro release kinetics of the optimized capsule containing 
Nicorandil loaded oil entrapped floating alginate beads, data obtained from dissolution 
study were plotted in various kinetics models. 
1. Zero order equation  
The zero order release can be obtained by plotting cumulative %  
Percentage drug released vs. time in hours. It is ideal for the formulation to have  
release profile of zero order to achieve pharmacological prolonged action. 
C=K0t 
Where K0= Zero order constant 
2. First order equation 
The graph was plotted as log % cumulative drug remaining Vs time in  
hours. 
Log C= log C0- Kt/2.303 
Where C0= Initial concentration of drug 
   K= First order 
t= Time in hours 
3. Higuchi kinetics 
The graph was plotted with % cumulative drug released Vs square root  
of time 
Q = Kt ½ 
Where K= constant reflecting design variable system (differential rate constant) 
t= Time in hours 
The drug release rate is inversely proportional to the square root of time 
4. Hixon and Crowell erosion equation 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixon and Crowell rate equation. 
The graph was plotted by cube root of % drug remaining vs. time in hours. 
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Q01/3 – Qt1/3 = KHCXt 
Where Qt= amount of drug released in time t. 
           Q0= Initial Amount of drug 
        KHC= Rate constant for Hixon Crowell equation 
5. Korsmeyer-Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in  
Peppas equation as log cumulative % of drug released Vs log time. 
Mt/Mα = Ktn 
Where Mt/Mα = Fraction of drug released at time t 
                 t = Release time 
                K= Kinetics constant (Incorporating structural and geometric characteristics of     
                     the formulation) 
              N= Diffusional exponent indicative of the mechanism of drug release 
 
 
9. RESULTS AND DISCUSSION 
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The present investigation was to formulate and evaluate Capsules containing 
Nicorandil loaded oil entrapped floating alginate beads for the treatment of Angina 
pectoris. 
PREFORMULATION STUDIES 
 
COMPATIBILITY STUDY 
The possible interactions between the drug and the excipients used in 
theformulation were studied by FTIR spectroscopy. The results are given below 
 
FTIR SPECTROSCOPY OF DRUG 
 
 
Fig.16 FTIR spectroscopy of Nicorandil 
 
Table9: IR spectral interpretation of Nicorandil 
 
Wave number(cm
-1
) Type of vibration 
1680 C=O stretching 
3250 N – H stretching 
3100 C – H (Aromatic) 
1600-1400 C – N stretching (Pyridine) 
1650 O - N  stretching 
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FTIR SPECTROSCOPY OF NICORANDIL WITH EXCIPIENTS 
 
 
Fig.17 FTIR spectroscopy of Nicorandil with Sodium alginate 
 
Table 10: IR spectral interpretation of Nicorandil with Sodium alginate 
 
Wave number(cm
-1
) 
 
Type of vibration 
1680 C=O stretching 
3250 N – H stretching 
3100 C – H (Aromatic) 
1600-1400 C – N stretching (Pyridine) 
1650 O – N stretching 
 
The results of IR spectra of active ingredient (Nicorandil) and sodium alginate 
revealed that therewas no considerable change observed in bands of Nicorandil. 
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Fig.18 FTIR spectroscopy of Nicorandil with HPMC K 100 M 
 
Table 11: IR spectral interpretation of Nicorandil with HPMC K 100 M 
 
Wave number(cm
-1
) Type of vibration 
1680 C=O stretching 
3250 N – H stretching 
3100 C – H (Aromatic) 
1600-1400 C – N stretching (Pyridine) 
1650 O – N stretching 
 
The results of IR spectra of active ingredient (Nicorandil) and HPMC K 100 M 
revealed that therewas no considerable change observed in the bands of Nicorandil. 
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Fig.19 FTIR spectroscopy of Nicorandil with Magnesium stearate 
 
Table 12: IR spectral interpretation of Nicorandil with Magnesium stearate 
 
Wave number(cm
-1
) Type of vibration 
1680 C=O stretching 
3250 N – H stretching 
3100 C – H (Aromatic) 
1600-1400 C – N stretching (Pyridine) 
1650 O – N stretching 
 
The results of IR spectra of active ingredient (Nicorandil) and  Magnesium 
stearate revealed that therewas no considerable change observed in the bands of 
Nicorandil. 
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FTIR SPECTROSCOPY OF NICORANDIL WITH BLEND 
 
Fig.20 FTIR spectroscopy of Nicorandil with blend 
 
Table 13: IR spectral interpretation of Nicorandil with blend 
 
Wave number(cm
-1
) Type of vibration 
1680 C=O stretching 
3250 N – H stretching 
3100 C – H (Aromatic) 
1600-1400 C – N stretching (Pyridine) 
1650 O – N stretching 
 
The results of IR spectra of active ingredient (Nicorandil) and the formulation 
blend revealed that there was no considerable change observed in the bands of 
Nicorandil. This shows the absence of anyinteraction between the drug and Excipients 
used in the formulation of Capsules containing Nicorandil loaded oil entrapped floating 
alginate beads. 
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CALIBRATION CURVE FOR NICORANDIL 
   The data for calibration curve of Nicorandil is given in table 14. 
Table 14: Data for calibration curve of Nicorandil 
CONCENTRATION 
(µg/ml) 
ABSORBANCE 
0 0 
2 0.052±0.0029 
4 0.108±0.0085 
6 0.163 ±0.0136 
8 0.217 ±0.0207 
10 0.274 ±0.0191 
R
2
=0.999 
 
 
 
 
 
 
 
 
Fig.21 Calibration curve of Nicorandil 
 It was found that the solutions of Nicorandil in 0.1 N HCl show linearity 
(R2=0.999) in   absorbance at concentrations of 2-10 μg/ml and obey beer Lambert’s 
Law.
72
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EVALUATION OF NICORANDIL LOADED OIL ENTRAPPED FLOATING 
ALGINATE BEADS 
PERCENTAGE YIELD 
The Percentage yield of FAB of batches F-1 to F-14 are listed in Table 15. 
Table 15:Percentage yield of FAB of batches F-1 to F-14 
 
Formula No. 
 
Percentage Yield 
%w/w 
F-1   80.82 
F-2 82.43 
F-3 93.29 
F-4 93.21 
F-5 87.28 
F-6 73.59 
F-7 94.25 
F-8 96.61 
F-9 60.37 
F-10 67.0 
F-11 87.91 
F-12 84.86 
F-13 54.66 
F-14 81.33 
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Fig. 22: Percentage yield of FAB of batches F-1 to F-14 
STUDY OF SIZE AND MORPHOLOGY OF ALGINATE BEADS 
MEAN DIAMETER 
Table 16: Mean diameter of FAB of batches F-1 to F-14 
 
Formula No. 
 
Mean diameter 
(mm)±S.D. 
(n=20) 
F-1 1.36±0.07 
F-2 1.34 ±0.06 
F-3 1.35 ±0.06 
F-4 1.33 ±0.08 
F-5 1.39 ±0.05 
F-6 1.41 ±0.09 
F-7 1.36 ±0.08 
F-8 1.38 ±0.06 
F-9 1.36 ±0.10 
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Formula No.  
 PERCENTAGE YIELD 
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F-10 1.46 ±0.16 
F-11 1.37 ±0.08 
F-12 1.42 ±0.06 
F-13 1.44 ±0.09 
F-14 1.40 ±0.07 
 
 
Fig.23:Mean diameter of FAB of batches F-1 to F-14 
The mean diameter of FAB of  batches F-1 to F-14 were found to be in the range 
of 1.33 to 1.44 mm as shown in table 16. 
MORPHOLOGY OF FLOATING ALGINATE BEADS 
The formulated FAB of batches F-1 to F-14 showed spherical geometry . The 
SEM photomicrograph of the entire bead structure and the cross-sectional view of the 
FAB of the optimized formulation F-5 shown in figures24 and 25 respectively reveals 
that the oil entrapped beads have an orange peel surface with corrugations where pores 
and channels are distributed throughout the surface.
16
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Fig.24SEM photomicrograph of FAB 
s  
Fig.25SEM photomicrograph of cross-sectional FAB 
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DENSITY 
Table 17:Density of FAB of batches F-1 to F-14 
 
Formula No. 
 
Density 
g/ml 
F-1 0.522 
F-2 0.500 
F-3 0.450 
F-4 0.482 
F-5 0.474 
F-6 0.469 
F-7 0.438 
F-8 0.484 
F-9 0.591 
F-10 0.537 
F-11 0.532 
F-12 0.529 
F-13 0.478 
F-14 0.581 
 
The bulk densities of various Nicorandil FAB formulas were found to be within 
the range (0.45-0.6g/ml) as shown in table 17, (i.e.) The density of all formulations 
obtained are less than the density of 0.1N HCl (1.004 g/ml).
16
Therefore the FAB float in 
0.1 N HCl. 
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% ENTRAPMENT EFFICIENCY, % DRUG LOADING 
Table 18: % Entrapment efficiency, % Drug loading of FAB of batches F-1 to F-14 
 
Formula no. 
 
% Entrapment 
efficiency 
(%w/w) 
 
% Drug loading 
(%w/w) 
F-1 78.72 16.23 
F-2 80.03 13.5 
F-3 87.59 5.85 
F-4 90.93 4.39 
F-5 93.04 10.69 
F-6 97.89 9.02 
F-7 82.77 6.83 
F-8 87.96 5.85 
F-9 69.84 9.09 
F-10 74.50 9.52 
F-11 83.61 8.60 
F-12 86.18 7.20 
F-13 66.80 10.69 
F-14 71.93 11.19 
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Fig.26: Percentage Entrapment efficiency of FAB of batches F-1to F-14 
The % EE of the FAB ranged from 66.8 to 97.89%w/v. It was found that formulas 
prepared with 2%w/v sodium alginate solution had much higher EE% than those 
prepared with 3%w/v and 4%w/v. This may be due to the increased viscosity of the 
alginate solution to the extent that the formation of drops was strongly held up, where 
inability of calcium ions to penetrate the thick and viscous dispersions of this 
concentration may occur. The calcium ions ability to penetrate the dispersion reduced, 
cross linking decreased hence drug entrapped within the beads decreased. It was found 
that the %EE increased for the batches prepared with 20%w/v of oil concentration 
compared to 15%w/v. The barrier action of entrapped oil droplets protected the drug 
against diffusion to the surrounding medium during gelation process.
15,16
 
 
 
 
 
 
 
0
20
40
60
80
100
F-
1
F-
2
F-
3
F-
4
F-
5
F-
6
F-
7
F-
8
F-
9
F-
1
0
F-
1
1
F-
1
2
F-
1
3
F-
1
4
%
 E
E 
(%
w
/v
) 
Formula No. 
PERCENTAGE ENTRAPMENT 
EFFICIENCY 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College. Page 88 
 
IN-VITRO FLOATING PROPERTIES 
Table 19: Floating lag time and Floating time of FAB of batches F-1 to F-14 
 
Formula 
No. 
 
Floating lag time 
(in seconds) 
 
Floating time 
F-1 2 >12 hours 
F-2 4 >12 hours 
F-3 2 >12 hours 
F-4 3 >12 hours 
F-5                    2 >12 hours 
F-6 2 >12 hours 
F-7 5 >12 hours 
F-8 3 >12 hours 
F-9 4 >12 hours 
F-10 2 >12 hours 
F-11 3 >12 hours 
F-12 3 >12 hours 
F-13 6 >12 hours 
F-14 2 >12 hours 
 
All the batches had floating time greater than 12 hours. Thus had very less 
floating lag time (2 to 6 seconds) as given in Table 19. This is due to the lower relative 
density (0.86) of Light liquid paraffin which helped the beads to become buoyant.
15,16
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SWELLING RATIO  
Table 20: Swelling ratio of FAB of batches F-1 to F-14 
Time 
(hrs) 
SWELLING RATIO 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
1 1.63 1.62 1.59 1.56 1.61 1.57 1.26 1.21 1.35 1.29 0.95 0.87 1.14 1.05 
2 1.67 1.65 1.61 1.58 1.63 1.60 1.29 1.24 1.39 1.33 1.05 0.91 1.18 1.08 
3 1.61 1.59 1.58 1.53 1.59 1.58 1.27 1.20 1.37 1.28 0.98 0.88 1.15 1.05 
4 1.58 1.55 1.53 1.47 1.55 1.54 1.23 1.17 1.34 1.26 0.92 0.85 1.12 1.03 
5 1.56 1.51 1.48 1.44 1.50 1.49 1.18 1.15 1.32 1.26 0.89 0.82 1.09 1.00 
6 1.56 1.49 1.44 1.39 1.48 1.45 1.15 1.13 1.29 1.24 0.88 0.81 1.07 0.99 
 
 
 
Fig. 27:Swelling ratio of FAB of batches F-1 to F-14 
            Swelling ratio of batches F-1 to F-14 for 6 hours is shown in the table 20.                   
The polymer concentration has significant effect on swelling ratio of beads. As the  
amount of polymer and the oil concentration was increased, the swelling ratio of beads  
get decreased.15
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IN-VITRO DRUG RELEASE STUDY 
Table 21:In-vitro drug release study of FAB of batches F-1 to F-14 
TIME 
(Hours) 
CUMULATIVE PERCENTAGE DRUG RELEASE(%) 
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 F-11 F-12 F-13 F-14 
1 21.24 24.48 14.67 17.91 34.29 27.81 11.34 14.67 24.48 27.80 14.67 17.91 21.25 24.48 
2 31.16 27.94 21.32 21.33 41.05 34.44 21.3 17.99 31.18 34.44 21.32 21.33 24.59 27.94 
3 37.91 34.58 31.24 24.64 44.60 41.20 24.66 24.66 34.29 37.96 24.67 28.02 31.30 34.58 
4 44.68 44.67 34.66 28.16 51.42 57.90 31.36 28.12 41.35 47.98 28.14 31.42 34.71 38.10 
5 51.50 51.48 38.18 28.31 61.51 67.68 31.53 28.28 44.91 54.81 34.78 34.80 41.47 41.55 
6 64.49 61.57 41.85 34.95 68.42 68.05 34.95 34.91 51.73 61.68 38.30 41.59 45.03 48.34 
7 78.33 71.72 45.18 38.47 75.36 75.00 41.71 45.00 58.58 65.35 41.74 45.15 48.51 55.18 
8 88.65 85.25 45.43 45.25 85.58 82.42 48.50 48.49 68.71 72.18 45.30 45.39 55.35 62.05 
9 98.95 98.86 48.91 48.73 89.37 88.99 52.10 48.75 75.65 82.48 52.12 48.88 58.98 67.14 
10   52.13 52.33 89.86 92.71 55.62 58.91 79.73 86.16 55.64 52.75 65.87 79.14 
11   62.60 59.18 96.90 99.79 62.49 62.45 83.06 89.96 59.27 55.99 76.03 82.89 
12   69.07 66.07 104.24 113.46 66.16 69.38 90.07 93.68 62.83 62.86 83.30 86.58 
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Fig.28:in-vitro drug release study of FAB of batches F-1 to F-6 
 
 
Fig. 29:in-vitro drug release study of FAB of batches F-7to F-10 
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Fig. 30: in-vitro drug release study of FAB of batches F-11 to F-14 
The drug release study of batches F-1 to F-14 were carried out and the percentage 
drug release from the FAB ranged from 66.16 to 113.46 at the end of 12 hours. The 
results showed that the drug release pattern was affected by polymer concentration, ratio 
of drug polymer mixture. All the batches showed the initial burst release. This may be 
due to the water-soluble nature of the drug. It may also be possible that the drug particles 
were dragged on the surface of the beads during curing in aqueous surrounding medium, 
which resulted in initial burst release. The results indicate that the drug release slows 
down with increasing polymer concentration. The batch which showed optimum drug 
release at the end of 12 hours was selected as the optimized formulation and it was found 
to be F-5. The percentage drug release was 104.24 %. My results corresponds to earlier 
reports.
15,16
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PREFORMULATION STUDIES OF CAPSULES 
FLOW PROPERTY MEASUREMENTS 
Table 22: Flow property measurements of FAB of the optimized batch F-5 
S.NO. Parameters Results Inference 
1. Bulk density 0.425±0.007 - 
2. Tapped density 0.4316± 0.0043 - 
3. Angle of Repose 18
0
 51’± 1.48 Excellent 
4. Carr’s index 2.13± 0.0711 Excellent 
5. Hausner’s ratio 1.021 ±0.00047 Excellent 
 
The results showed that the prepared FAB possess excellent flow property so the 
use of glidant is not required. 
EVALUATION OF CAPSULES 
               The disintegration time of the empty capsule was found to be 12 minutes. This 
complies with the official standard.  
Table 23: Uniformity of weight of the optimized batch F-5 
S.No. Parameters Results 
1. Uniformity of weight* 0.1830±0.0004 
*Mean±SD(n=20) 
The capsules had uniformity of weight. The result complies with the standard. 
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IN-VITRO DRUG RELEASE STUDY OF OPTIMIZED AND MARKETED 
FORMULATION 
Table 24: Comparison table of in-vitro drug release study of optimized and 
marketed formulation 
 
                                                 * MEAN±SD(n=2) 
 
Fig. 31: in-vitro drug release study of the optimized and marketed formulation 
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IN-VITRO DRUG RELEASE STUDY OF 
OPTIMIZED AND MARKETED FORMULATION 
F-5
Marketed formulation
 
Time(Hours) 
 
 
F-5* 
 
Marketed Formulation* 
1 29.43±1.62 29.35±0.001 
2 37.73± 3.27 32.93±0.001 
3 44.51 ±3.29 37.24±0.9 
4 51.33 ±3.31 44.20± 2.48 
5 58.18 ±3.33 46.99±1.71 
6 63.45 ±1.6 51.44±2.51 
7 71.17 ±4.04 57.63 ±1.69 
8 80.56 ±1.7 64.59 ±1.62 
9 87.55 ±1.64 72.36 ±0.56 
10 91.32 ±1.58 77.89±5.7 
11 93.58 ±3.26 84.31 ±6.75 
12 98.88 ±1.61 97.4 ±0.78 
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The in-vitro drug release study of the optimized and marketed formulation 
showed that the drug release pattern of the capsule containing optimized formulation was 
similar to that of the marketed formulation. 
IN-VITRO RELEASE KINETICS
14,15
 
The values obtained from in-vitro dissolution of the capsules containing 
Nicorandil loaded oil entrapped floating alginate beads were fitted in various kinetic 
models. The results are given in table 25 and figures 32-36.  
Table 25:in-vitro release kinetics of the optimized batch F-5 
Time 
(Hours) 
Log 
time 
(Hours) 
Sq. 
Root of 
time 
(Hours) 
Cum 
% 
drug 
release 
Cum % 
drug 
remaining 
Log 
cum % 
drug 
release 
Log cum 
% drug 
remaining 
Cube root 
of cum % 
drug 
remaining 
0 ∞ 0 0 100 ∞ 2 4.64 
1 0 1 29.43 70.57 1.46 1.84 4.13 
2 0.30 1.41 37.73 62.27 1.57 1.79 3.96 
3 0.47 1.73 44.51 55.49 1.64 1.74 3.81 
4 0.60 2 51.33 48.67 1.71 1.68 3.65 
5 0.69 2.23 58.18 41.82 1.76 1.62 3.47 
6 0.77 2.44 63.45 36.55 1.80 1.56 3.31 
7 0.84 2.64 71.17 28.83 1.85 1.45 3.04 
8 0.90 2.82 80.56 19.44 1.90 1.28 2.68 
9 0.95 3 87.55 12.45 1.94 1.09 2.31 
10 1 3.16 91.32 8.68 1.96 0.93 2.05 
11 1.04 3.31 93.48 6.52 1.97 0.81 1.86 
12 1.07 3.46 98.88 1.12 1.99 0.04 1.03 
 
 
 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College. Page 96 
 
ZERO ORDER KINETICS 
 
 Fig. 32:Zero order release kinetics  
 
 
 
FIRST ORDER KINETICS 
 
Fig.33:First order kinetics 
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HIGUCHI RELEASE KINETICS 
 
Fig. 34:Higuchi release kinetics 
 
 
 
KORSMEYER-PEPPAS KINETICS 
 
Fig. 35:Korsemeyer -Peppas kinetics 
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HIXON-CROWELL KINETICS 
 
Fig. 36: Hixson - Crowell kinetics  
DETERMINATION OF RELEASE KINETICS OF OPTIMIZED 
FORMULATION 
 After studying the different kinetics models, it could be concluded that 
release of Nicorandil from batch F-5 followed the Higuchi model i.e. 
square root kinetics in which R
2 
value was 0.989. Thus the release from 
these batches was diffusion controlled. 
 The n value of Korsmeyer- Peppas equation was found to be 0.522, from 
that it was concluded that the release followed non- fickian transport. 
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 The present study was aimed to develop Capsules containing Nicorandil loaded oil 
entrapped floating alginate beads by varying sodium alginate concentration viz 2,3 and 
4%w/v, Drug:Alginate ratio viz 1:0.5, 1:2,1:1 and oil (Liquid paraffin) concentration viz 
15%v/v and 20%v/v. 
 Chemical compatibility study was performed using FTIR spectroscopy and FTIR studies             
revealed that there was no change in major peaks thus confirming no interaction between             
the drug and excipients. 
 Nicorandil loaded floating alginate beads was prepared by Emulsion Gelation method 
using sodium alginate, HPMC K100M, Liquid paraffin. 
 The formulated FAB were evaluated for Percentage yield, Size and Morphology, 
%Entrapment efficiency, %Drug loading, Density, in-vitro floating properties, in-vitro 
drug release studies. 
 Based on the in-vitro drug release studies, the optimized formulation was selected and it 
was found to be F-5. 
 The preformulation studies were carried out for the optimized formulation F-5 to 
determine the flow property of the FAB. The results revealed that the beads possess 
excellent flow property. Nicorandil-loaded oil-entrapped beads equivalent to 20 mg of  
Nicorandil equivalent weight were mixed with magnesium stearate (5%, w/w) as 
lubricating agent for additional 3 min and filled into empty hard gelatin capsule. 
 The formulated capsules were evaluated for uniformity of weight, Disintegration time 
and in-vitro drug release study. The formulated capsules were found to be within the limit 
in case of uniformity of weight. 
 The capsule containing Nicorandil loaded floating alginate beads was compared with the 
Marketed prolonged release formulation. The results showed excellent similarity. 
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 The release kinetics of the capsule containing the optimized Nicorandil loaded oil 
entrapped FAB showed that it follows Higuchi release kinetics. The release of the drug 
from the dosage form is carried out by diffusion and follows Korsmeyer peppas kinetics 
and the n value is greater than 0.5 indicating non-Fickian release. 
 The floating beads have been employed to make a sustained release of the drug in the 
stomach to enhance bioavailability and to decrease dose dumping and hence overcome its 
side effects. 
 The developed formulation shows an alternative to the conventional dosage form for the             
treatment of Angina pectoris in patients. 
 
FUTURE PLAN 
 Scale up studies of the optimized formulation. 
 In-vivo studies and in vivo- in vitro correlation studies. 
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